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1.INTRODUCTION 
 
 
 
1.1. Novel Drug Delivery System: 
 
(Chein Y.W., 2002; Bandyopadhyay   A.K., 2008; Vyas   S.P., 2009) 
 
For many decades, the treatment of an acute disease or a chronic illness has 
been mostly accomplished by the delivery of drugs to the patients using various 
pharmaceutical  dosage forms such as tablets, capsules, pills, suppositories,  creams, 
ointments,  aerosols  and  injectable.  Even  today  these  conventional  drug  delivery 
systems are the primary pharmaceutical products commonly seen in the prescriptions 
and which are available as over- the- counter medicines. The method by which a drug 
is delivered  can have a significant  effect on its efficacy. The slow progress in the 
treatment  of certain  disease  has suggested  a growing  need  for a multidisciplinary 
approach  to the delivery  of drugs  to their  target  sites.  Recently,  several  technical 
advancements have resulted in the development of new techniques which are capable 
of controlling the rate of drug delivery, sustaining the duration of therapeutic activity 
and or targeting the delivery of drug to a tissue. These are referred to as novel drug 
delivery system. 
And they have revolutionized the method of medication, provides a number of 
therapeutic benefits. These drug delivery systems are based interdisciplinary approach 
that   combines   polymer   science,   pharmaceutics,   bioconjugated   chemistry   and 
molecular biology. 
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1.1.1.   Advantages of Novel Drug Delivery Systems: 
 
(Shoba Rani R Hire math., 2008) 
 
™ Improved  therapy  by  increasing  the  duration  of  action  and  reduced  side 
effects. 
™ Increase  the  patient  compliance  through  decreased  dosing  frequency  and 
convenient routs of administration. 
™ Achieve targeting of drugs to a specific site to reduce unwanted side effects 
and obtain maximum efficacy. 
™ Lead to reduction in dose and thus reduction in side effects of drugs. 
 
1.2.   Rational For Targeted Drug Delivery System: 
 
(Shoba Rani R Hire math., 2008) 
 
Most of the drug introduced  to clinical  medicines  produce  their effects  by 
interacting with cell and cell membrane-related structures and function through 
concentration-dependent, reversible interaction at a specific receptor sites. Obviously, 
to obtain the desirable  therapeutic  response,  the correct amount of drug should be 
transported  and delivered  to the site of action with subsequent  control of the drug 
input rate. The efficacy of many drugs is often limited by their potential to reach their 
therapeutic site of action. In most cases, only a small amount of the administered dose 
of the drug actually reaches this site, while most of the drug is distributed to the rest 
of the body depending on the physiochemical and biochemical properties of the drug. 
Most drugs, when administered in conventional or controlled release dosage 
forms, freely travel throughout the body, leading to uptake by cells, tissue or organs 
other than those that contain their pharmacological receptors. This distribution of the 
drug  to  other  tissues  is  unnecessary,  wasteful  and  a  potential  cause  of  toxicity. 
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This lack of target specificity can be attributed to the formidable barriers that the body 
presents to a drug. A drug taken orally must withstand large fluctuations in pH as well 
as the action of enzymes before it get absorbed. Moreover, it needs to survive 
inactivation by the hepatic first pass effect. To produce a therapeutic effect, the drug 
must selectively access and interaction with the pharmacological  receptors, and the 
concentration of the drug at the active site must be adequate. 
1.3.   Nanotechnology:                                               (Shoba Rani R Hire math., 2008) 
 
Nanoparticles are solid colloidal particles ranging 10-1000nm (1µm) in size. 
They consist of macromolecular  in which the active ingredient  (drug or biological 
active material) is dissolved, entrapped or encapsulated, and/or adsorbed or attached. 
Depending  on the process  used for the preparation,  two types of nanoparticle  are 
obtained: nanospheres and nanocapsules. 
Nanospheres  have  a  matrix-type  structure  in  which  the  drug  is  dispersed, 
whereas nanocapsule exhibits a membrane-wall structure with an oily core containing 
drug. As nanoparticulate systems have a very high surface area, drug may also absorb 
on their surface. Nanoparticles are made of artificial or natural polymer. The use of 
these polymers is often restricted by their biocompatibility. 
 
 
Fig. 1.1: Structure of nanospheres and nanocapsules 
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After preparation, nanoparticles are usually dispersed in liquid. Such a system 
can be administered to humans for example by injection, by the oral route, or used in 
ointments and ocular products. Alternatively, nanoparticles can be dried to a powder, 
which allows pulmonary delivery or further processing to tablets or capsules. 
In drug delivery, nanoparticles should readily be biocompatible (not harmful 
for  humans)  and  biodegradable  (deteriorate  and  expulse  in  the  body  conditions). 
These properties, as well as targeting and controlled release, can be affected by 
nanoparticle   material  selection  and  by  surface  modification.   Materials  such  as 
synthetic  polymers,  proteins  or  other  natural  macromolecules   are  used  in  the 
preparation of nanoparticles. 
1.3.1. Advantages of Nanoparticles: 
 
™ Enhancement   of   therapeutic   effectiveness   of   the   drug   i.e.   the   overall 
pharmacological response per unit dose in increased. 
™ Toxicity and adverse drug interactions are reduced to a possible extent. 
 
E.g.  polymethacrylic  nanoparticles  for  targeting  anticancer  drug  of 
doxorubicin to reduce liver toxicity. Nanoparticles posses‘ better stability as 
compared  to liposome‘s  which make it more important  for many modes of 
targeting. 
™ Nanoparticles   formulated   as   amorphous   offer   solubility   than   standard 
crystalline  formulations,  thus  improving  the poor  aqueous  solubility  of the 
drug and hence the bioavailability. 
 
™ The methods of preparation are simple, easier and reproducible. 
 
™ A high degree of patient compliance can be achieved. 
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™ Wide range of polymer can be used depends on the nature of the drug and 
usage i.e. biodegradable polymer for shorter periods, and non-biodegradable 
for longer periods. 
 
™ It  can  easily  pass  through  syringe  needle  and  exhibit  good  rheological 
properties. 
1.3.2. Limitations of Nanoparticles: 
 
™ Their  small  size  and  large  surface  area  can  lead  to  particles  aggregation, 
making  physical  handling   of  nanoparticles   difficult   in  liquid  and  drug 
formulations. 
™ In addition, small particle size and large surface area readily result in limited 
drug loading and burst release. These practical problems have to be overcome 
before nanoparticles can be used clinically or made commercially available. 
 
1.3.3. Advantages over Microparticles:                   (Ronald J. Neufeld., 2006) 
 
™ They have higher intracellular uptake compared to micro particles. 
 
™ They are better suited for I.V. delivery since the smallest blood capillaries in 
then body is about 5-6μm. 
1.3.4. Advantages over Liposomes: 
 
™ They have better stability in biological fluids and during storage. 
 
™ Their preparation is more amenable to scale up. 
 
They have the unique ability to create a controlled release product. 
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1.4. Types of Nanoparticles:                                     (Pushpendra Goswami., 2011) 
 
™ Fullerenes: Bucky balls and carbon tubes: 
 
Both members of the fullerene structural class, bucky balls and carbon tubes are 
carbon based lattice-like, potentially porous molecules. 
™ Liquid crystals: 
 
Liquid crystal pharmaceuticals  are composed of organic liquid crystal materials 
that  mimic   naturally-occurring   biomolecules   like  proteins   or  lipids.   They   are 
considered a very safe method or drug delivery and can target specific areas of the 
body where tissues are inflamed, or where tumors are found. 
™ Liposomes: 
 
Liposomes are lipid-based liquid crystals, used extensively in the pharmaceutical 
and cosmetic industries because of their capacity for breaking down inside cells once 
their   delivery   function   has   been   met.   Liposome‘s   were   the   first   engineered 
nanoparticles  used for drug delivery but problems  such as their propensity  to fuse 
together in aqueous environments and release their payload, have lead to replacement, 
or stabilization using newer alternative nanoparticles. Liposomal formulations are the 
first NanoPharmaceuticals introduced to market, Doxil® PEGylated liposomal 
formulation for doxorubicin is the first product based on liposomes. 
™ Nanoshells: 
 
Also referred to as core-shells, nanoshells are spherical cores of a particular 
compound  surrounded  by  a  shell  or  outer  coating  of  another,  which  is  a  few 
nanometers thick 
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™ Quantum dots: 
 
Also known  as nanocrystals,  quantum  dots are nanosized  semiconductors  that, 
depending  on  their  size,  can  emit  light  in  all  colours  of  the  rainbow.  These 
nanostructures confine conduction band electrons, valence band holes, or excitons in 
all three special directions. Examples of quantum dots are semiconductor nanocrystals 
and   core   shell   nanocrystals,   where   there   is   an   interface   between   different 
semiconductor materials. They have been applied in biotechnology  for cell labeling 
and imaging, particularly in cancer imaging studies. 
™ Superparamagnetic nanoparticles: 
 
Superparamagnetic  molecules are those that are attracted to a magnetic field but 
do not retain residual  magnetism  after the field is removed.  Nanoparticles  of iron 
oxide with diameters in the 5-100 nm range have been used for selective magnetic 
bioseparations.  Typical  techniques  involve  coating  the particles  with  antibodies  to 
cell-specific antigens, for separation from the surrounding matrix. 
™ Dendrimers: 
 
Dendrimers are highly branched structures gaining wide use in nanomedicine 
because of the multiple molecular ―hooks‖ on their surfaces that can be used to attach 
cell-identification tags, fluorescent dyes, enzymes and other molecules. The first 
dendritic molecules were produced around 1980, but interest in them has blossomed 
more recently as biotechnological uses are discovered. 
™ Nanorods: 
 
Typically 1-100 nm in length, nanorods are most often made from semiconducting 
materials and used in nanomedicine as imaging and contrast agents. Nanorods can be 
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made by generating small cylinders of silicon, gold or inorganic phosphate, among 
other materials. 
1.5. Polymers Employed as Nanoparticle:                                       (Gadad A., 2011) 
 
1.5.1. Natural polymers used for the preparation of nanoparticles: 
 
™ Proteins: 
 
¾ Gelatin 
 
¾ Albumin 
 
¾ Lectins 
 
¾ Legumin 
 
¾ Vicilin 
 
™ Polysaccharides: 
 
¾ Alginate 
 
¾ Dextran 
 
¾ Chitosan 
 
¾ Agarose 
 
¾ Pullulan 
 
1.5.2. Synthetic polymers used for the preparation of nanoparticles: 
 
™ Pre-polymerized: 
 
¾ Poly (ε – caprolactone) 
 
¾ Poly (lactic acid) 
 
¾ Poly (lactide-co-glycolide) 
 
¾ Polystyrene 
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™ Polymerized in process: 
 
¾ Poly (isobutylcyanoacrylates) 
 
¾ Poly (butylcyanoacrylates) 
 
¾ Poly (hexylcyanoacrylates) 
 
¾ Poly methyl (methacrylate) 
 
1.6. Preparation Techniques of Nanoparticles: 
 
1.6.1. Synthetic performed polymers: (Ronald J. Neufeld., 2006; Behera A.L., 2010) 
 
A.  Emulsification/solvent evaporation: 
 
Emulsification-solvent  evaporation involves two steps. The first step requires 
emulsification of the polymer solution into an aqueous phase (see Fig. 1.2). During 
the second step polymer solvent is evaporated, inducing polymer precipitation as 
nanospheres. 
A polymer  organic solution  containing  the dissolved  drug is dispersed  into 
nanodroplets,   using  a  dispersing   agent  and  high-energy   homogenization,   in  a 
nonsolvent or suspension medium such as chloroform (ICH, class 2) or ethyl acetate 
(ICH, class 3). The polymer precipitates in the form of nanospheres in which the drug 
is finely dispersed in the polymer matrix network. The solvent is subsequently 
evaporated  by increasing  the temperature  under pressure or by continuous  stirring. 
The  size  can  be  controlled  by  adjusting  the  stirring  rate,  type  and  amount  of 
dispersing  agent,  viscosity  of organic  and aqueous  phases,  and temperature.  Even 
though different types of emulsions may be used, oil/water emulsions are of interest 
because they use water as the nonsolvent, this simplifies and thus improves process 
economics, because it eliminates the need for recycling, facilitating the washing step 
and minimizing agglomeration. 
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However, this method can only be applied to liposoluble drugs, and limitations 
are imposed by the scale-up of the high energy requirements in homogenization. 
Frequently used polymers are PLA, PLGA, ethylcellulose (EC), cellulose acetate 
phthalate, poly (E-caprolactone) (PCL) and poly (hydroxybutyrate) (PHB). Drugs or 
model  drugs  encapsulated  were albumin,  texanus  toxoid,  testosterone,  loperamide, 
prazinquantel, cyclosporin A, nucleic acid, and indomethacin. 
 
 
Fig. 1.2: Schematic representation of the emulsification-evaporation technique 
 
B.  Solvent displacement and interfacial deposition: 
 
Solvent displacement and interfacial deposition are similar methods based on 
spontaneous emulsification of the organic internal phase containing the dissolved 
polymer   into   the   aqueous   external   phase   (see   Fig.   1.3).   However,   solvent 
displacement  forms  nanospheres  or  nanocapsules,  whereas  interfacial  deposition 
forms only nanocapsules. 
Solvent displacement involves the precipitation of a preformed polymer from 
an organic solution and the diffusion of the organic solvent in the aqueous medium in 
the presence or absence of a surfactant. The polymer, generally PLA, is dissolved in a 
water-miscible   solvent  of  intermediate  polarity,  leading  to  the  precipitation   of 
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nanospheres.  This  phase  is  injected  into  a  stirred  aqueous  solution  containing  a 
stabilizer as a surfactant. Polymer deposition on the interface between the water and 
the organic solvent, caused by fast diffusion of the solvent, leads to the instantaneous 
formation of a colloidal suspension. To facilitate the formation of colloidal polymer 
particles during the first step of the procedure, phase separation is performed with a 
totally miscible solvent that is also a nonsolvent of the polymer. 
 
 
Fig. 1.3: Schematic representation of the solvent displacement technique 
 
The solvent displacement  technique allows the preparation  of nanocapsules 
when a small volume of nontoxic oil is incorporated in the organic phase. Considering 
the  oil-based  central  cavities  of  the  nanocapsules,  high  loading  efficiencies  are 
generally   reported   for  lipophilic   drugs   when   nanocapsules   are   prepared.   The 
usefulness of this simple technique is limited to water-miscible solvents, in which the 
diffusion rate is enough to produce spontaneous  emulsification.  Then, even though 
some water-miscible solvents produce certain instability when mixed in water, 
spontaneous  emulsification  is  not  observed  if  the  coalescence  rate  of  the  formed 
droplets is sufficiently  high. Although,  acetone/dichloromethane  (ICH, class 2) are 
used to dissolve and increase the entrapment of drugs, the dichloromethane increases 
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the mean particle size and is considered toxic. This method is basically applicable to 
lipophilic drugs because of the miscibility of the solvent with the aqueous phase, and 
it is not an efficient means to encapsulate water soluble drugs. 
C.  Emulsification/solvent diffusion: 
 
Emulsification/solvent diffusion (ESD) was proposed in the literature based on 
the use of organic solvents, and then it was adapted to the following salting-out 
procedure. The encapsulating polymer is dissolved in a partially water soluble solvent 
such as propylene carbonate (ICH not given) and saturated with water to ensure the 
initial thermodynamic equilibrium of both liquids. In fact, to produce the precipitation 
of  the  polymer  and  the  consequent  formation  of  nanoparticles,  it  is  necessary  to 
promote the diffusion of the solvent of the dispersed phase by dilution with an excess 
of  water  when  the  organic  solvent  is  partly  miscible  with  water  or  with  another 
organic  solvent  in  the  opposite  case.  Subsequently,  the  polymer-water  saturated 
solvent phase is emulsified  in an aqueous solution containing stabilizer, leading to 
solvent  diffusion   to  the  external   phase  and  the  formation   of  nanospheres   or 
nanocapsules, according to the oil-to-polymer ratio. Finally, the solvent is eliminated 
by evaporation or filtration, according to its boiling point. The procedure is illustrated 
in Fig. 1.4. 
This technique presents several advantages, such as high encapsulation 
efficiencies (generally N70%), no need for homogenization, high batch-to-batch 
reproducibility,  ease of scale-up,  simplicity,  and narrow  size distribution. 
Disadvantages  are the high volumes of water to be eliminated from the suspension 
and  the  leakage  of  water-soluble  drug  into  the  saturated-aqueous  external  phase 
Acyclovir Loaded pH Sensitive Nanoparticle Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 13 
 
 
 
during emulsification, reducing encapsulation efficiency. As with some of the other 
techniques, this one is efficient in encapsulating lipophilic drugs 
 
 
Fig. 1.4: Schematic illustration of the ESD technique 
 
Several drug-loaded  nanoparticles  were produced  by the ESD technique,  including 
mesotetra(hydroxyphenyl) porphyrin-loaded PLGA (p-THPP) nanoparticles, 
doxorubicin-loaded PLGA nanoparticles, plasmid DNA-loaded PLA nanoparticles, 
coumarin-loaded PLA nanoparticles, indocyanine, cyclosporine (Cy-A)-loaded gelatin 
and cyclosporin (Cy-A)-loaded sodium glycolate nanoparticles. 
D.  Salting out with synthetic polymers: 
 
Salting-out  is  based  on  the  separation  of  a  water  miscible  solvent  from 
aqueous solution via a salting-out effect. The salting-out procedure can be considered 
as  a  modification  of  the  emulsification/solvent  diffusion.  Polymer  and  drug  are 
initially dissolved in a solvent such as acetone, which is subsequently emulsified into 
an aqueous gel containing the salting-out agent (electrolytes, such as magnesium 
chloride,  calcium  chloride,  and  magnesium  acetate,  or  non-  electrolytes  such  as 
sucrose)  and  a  colloidal  stabilizer  such  as  polyvinylpyrrolidone  or 
hydroxyethylcellulose.  This oil/water emulsion is diluted with a sufficient volume of 
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water or aqueous solution to enhance the diffusion of acetone into the aqueous phase, 
thus inducing the formation of nanospheres. The selection of the salting out agent is 
important, because it can play an important role in the encapsulation efficiency of the 
drug. Both the solvent and the salting-out  agent are then eliminated  by cross-flow 
filtration. 
This technique used in the preparation of PLA, poly- (methacrylic) acid, and 
EC nanospheres leads to high efficiency and is easily scaled up. The main advantage 
of salting out is that it minimizes stress to protein encapsulants. Salting out does not 
require an increase of temperature and, therefore, may be useful when heat sensitive 
substances have to be processed. The greatest disadvantages are exclusive application 
to lipophilic drugs and the extensive nanoparticle washing steps. The preparative steps 
of this procedure are described in Fig. 1.5. 
 
 
Fig. 1.5: Schematic diagram of the salting-out technique 
 
1.6.2. Production of nanoparticles from natural macromolecules: 
 
A.  Albumin nanoparticles produced in an external-oily emulsion: 
 
Two main methods are used in the preparation of albumin microspheres, 
characterized   by   the   method   of   stabilization,   thermal   treatment   at   elevated 
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temperatures   (958–1708ºC)   or  chemical   treatment   in  vegetable   oil,  iso-octane 
emulsions, or aqueous medium. Other techniques involve slight modification of either 
of the two methods In this case albumin nanospheres were formed by homogenizing 
the oil phase containing the albumin droplets and thermally stabilized by heating at 
1758 - 1808ºC for 10 minutes. This mixture was cooled and diluted with ethyl ether to 
reduce the viscosity of the oil phase to permit separation by centrifugation. 
Heat treatment of albumin is applicable only to drug molecules that are not 
heat  sensitive.  For  this  reason,  nanoparticles  were  produced  emulsifying  serum 
albumin aqueous solution in cottonseed oil at 258ºC, then denaturing the albumin by 
resuspending the particles in ether containing the cross-linking agents 2,3-butadiene 
or formaldehyde. The particles were stirred, isolated by centrifugation, and dried by 
lyophilization.  Particles  released  the  drug  doxorubicin  much  faster  than  particles 
formed by heat treatment, but the purification step remains the main problem with the 
elimination of the cottonseed oil. A technique was proposed based on the desolvation 
of natural macromolecules, which simplifies the purification step. 
As  a  modification  of  this  method,  an  aqueous  solution  of  albumin  was 
emulsified  in chloroform  containing  hydroxypropylcellulose  and EC as stabilizers. 
The emulsified macromolecule is subsequently cross-linked with glutaraldehyde and 
washed. Because of the need for chlorinated solvents, this technique does not offer 
much advantage over the other techniques. 
B.  Gelatin nanoparticles produced in an external-oily emulsion: 
 
Emulsified gelatin solution droplets were hardened by cooling the emulsion 
below the gelation point in an ice bath, resulting in gelation of the gelatin droplets. 
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Gelled nanodroplets were filtered, washed, and cross-linked with formaldehyde. The 
particle size ranged between 100 and 600 nm with a mean of 280 nm. This technique 
is applicable to heat-sensitive drugs; however, a number of drugs can be covalently 
bound to the gelatin by formaldehyde  treatment,  which constitutes  a disadvantage. 
Additionally,   cross-linking   increases   significantly   the   size   of   the   particles. 
Furthermore,  a  significant  disadvantage  of  the  cross-linking  agent  relates  to  its 
toxicity, and this point must be carefully considered. In this context, it would be of 
interest   to  study   carefully   the  influence   of  different   formulation   and  process 
parameters in this process according to the application. 
Another interesting system for drug delivery systems could be nanoparticulate 
carriers  from  bioacceptable   macromolecules.   For  this  reason,  vegetable  protein 
fractions   termed  gliadins  have  been  chosen  from  wheat  gluten,  to  efficiently 
encapsulate lipophilic substances such as a-tocopherol. Gliadins possess the ability to 
interact with epidermal keratin as a result of their richness in praline; this property 
leads to a desired controlled release of drug. 
C.  Alginate nanoparticles: 
 
Sodium alginate is a water-soluble polymer that gels in the presence of 
multivalent cations such as calcium. Alginate particles are usually produced by drop 
wise extrusion of sodium alginate solution into calcium chloride solution. Alginate 
particle size depends on the size of the initial extruded droplet. The smallest particles 
produced  had  a  minimum  size  of  1  to  5  Am,  obtained  by  air  atomization.  The 
preparation of alginate nanoparticles was first achieved in a diluted aqueous sodium 
alginate solution in which gelation was induced by the addition of a low concentration 
of calcium. 
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Fig. 1.6: Schematic representation  of the emulsification–internal  gelation technique 
using alginate. 
This leads to the formation of invisible clusters of calcium alginate gels. In an 
additional advance, alginate particles have been produced by using a modified 
emulsification/internal gelation method. The preparation of alginate nanoparticles via 
this method does not require specialized equipment and can be performed at ambient 
temperature. The main difficulty of this method is the nanoparticle washing step to 
eliminate the residual oil droplets, but new strategies have been devised. 
D.  Chitosan nanoparticles: 
 
Chitosan nanoparticles have been developed to encapsulated proteins such as 
bovine  serum  albumin,  tetanus  and  diphtheria  toxoid,  vaccines,  anticancer  agents, 
insulin, and nucleic acids. Chitosan considerably enhanced the absorption of peptides 
such as insulin and calcitonin across the nasal epithelium. 
The methods proposed to prepare chitosan nanoparticles are based on the 
spontaneous formation of complexes between chitosan and polyanions or the gelation 
of a chitosan solution dispersed in an oil emulsion. Various methods for producing 
chitosan nanoparticles are described in the literature. 
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Chitosan  nanoparticles  obtained  by  formation  of  a spontaneous  complex  between 
chitosan and polyanions such as tripolyphosphate have small diameters (200–500 nm) 
and show a quasi spherical shape under transmission electron microscopy. Chitosan 
nanoparticles produced by a promoting gelation in an emulsification-based method as 
illustrated in Fig. 1.7, results in a diameter of 400 nm. 
Compared with the previously described method, this technique has a major 
disadvantage of involving organic solvents during the isolation of the particles; these 
are difficult to remove and may cause toxicity. 
 
 
Fig. 1.7: Schematic representation of chitosan nanoparticles preparation by the 
emulsification technique 
E.  Agarose nanoparticles: 
 
Agarose  nanoparticles  were developed  for the administration  of therapeutic 
proteins and peptides. Agarose aqueous solution forms thermally reversible hydrogels 
while  being  cooled  below  the  gelling  temperature  (318–368ºC).  Thermal  gelation 
results from the formation of helicoidal structures responsible for a three-dimensional 
network  in which  large  amounts  of water  can  be entrapped.  The  hydrogel,  being 
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hydrophilic,  inert,  and  biocompatible,  forms  a  suitable  matrix  for  proteins  and 
peptides that can be entrapped in the gel during formation. 
 
 
Fig.  1.8:  Schematic  representation   of  agarose  nanoparticles  preparation  by  the 
emulsification technique 
This methodology requires the preparation of an agarose solution in corn oil 
emulsion at 408ºC. Peptides and proteins to be encapsulated are initially added to the 
agarose solution. The small size of the dispersed aqueous nanodroplets is achieved by 
homogenization.  Gelation of agarose is then induced by diluting the emulsion with 
cold corn oil under agitation  at 58ºC. The liquid nanodroplets  then gel to protein- 
containing agarose hydrogel nanoparticles. 
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1.7. Characterization of Nanoparticles:   (Gadad A., 2011; Mohanraj V. J., 2006) 
 
Table 1.1: Characterization of nanoparticles 
 
S.NO PARAMETERS METHODS 
1 Particle size and morphology Transmission electron microscopy, 
scanning (electron, force, tunneling) 
microscopy freeze-fracture electron 
microscopy, Photon-correlation 
spectroscopy. 
2 Surface charge 
 
Surface hydrobhobicity 
Zeta potential measurement Hydrophobic 
interaction chromatography Contact angle 
measurement 
3 Density Helium compression pyenometry 
 
Density gradient centrifugation 
4 Molecular weight  Crystallinity Gel permeation chromatography 
 
X-ray diffraction, Differential 
scanning calorimetory 
5 Surface charge 
 
Surface hydrobhobicity 
Contact angle measurements 
Hydrophobic interaction chromatography 
Zeta potential measurement 
6 Carrier drug interactions DSC 
7 Nanoparticle dispersion stability Critical flocculation temperature(CFT) 
8 Surface Chemical analysis secondary ion mass spectroscopy 
x- ray photoelectron spectroscopy 
nuclear magnetic resonance 
Fourier transform infrared spectroscopy 
9 Release profile In-vitro release characteristics under 
physiologic and sink conditions 
10 Drug stability Bioassay of drug extracted from 
nanoparticle chemical analysis of drug 
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A.  Freeze-drying:                                    (Saez A., 2000; Randolph TW., 1999) 
 
Briefly,  in freeze-drying  (lyophilization),  solvent  (e.g. Water)  in the system  is 
frozen followed by its sublimation in vacuum. At present, freeze-drying is the method 
of choice  to remove  water  from the system in nanoparticle  formulations  and also 
avoids instability  problem  of liquid preparation  if it is done effectively.  However, 
freeze-drying  of nanoparticles  is a complicated  process because the stability of the 
colloidal nanoparticle dispersion in most cases disturbed leading to aggregation before 
the particulate population is dry. Several variables affect the final result: freezing rate 
and temperature, drying temperatures, pressure, use of excipients like bulking agents 
or cryo-  and lyoprotectants  and changes  in pH or ionic strength.  After  successful 
drying, one should be able to re-disperse particles in their initial dispersing medium 
without causing significant changes in their size and drug content. 
Cryoprotectants  protect  the product  during  freezing,  whereas  lyoprotectants 
provide stability  during the drying step. Glycine,  sucrose,  glucose  and poly (vinyl 
pyrrolidone)  are  Cryoprotectants,  while  disaccharides  such  as  trehalose,  sucrose 
lactose act usually as lyoprotectants. 
B.  Particle size: 
 
Particle  size  and size distribution  are the  most  important  characteristics  of 
nanoparticle systems. They determine the in vivo distribution, biological fate, toxicity 
and the targeting ability of nanoparticle systems. In addition, they can also influence 
the drug loading, drug release and stability of nanoparticles. Many studies have 
demonstrated that nanoparticles of sub-micron size have a number of advantages over 
microparticles as a drug delivery system. 
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Generally nanoparticles  have relatively higher intracellular  uptake compared 
to microparticles and available to a wider range of biological targets due to their small 
size  and  relative  mobility.  In  a  subsequent  study,  the  nanoparticles  penetrated 
throughout the submucosal layers in a rat in situ intestinal loop model, while 
microparticles  were  predominantly  localized  in  the  epithelial  lining.  It  was  also 
reported that nanoparticles can across the blood-brain barrier following the opening of 
tight junctions by hyper osmotic mannitol, which may provide sustained delivery of 
therapeutic agents for difficult-to-treat  diseases like brain tumors. Tween 80 coated 
nanoparticles  have been shown to cross the blood-brain barrier. In some cell lines, 
only submicron nanoparticles can be taken up efficiently but not the larger size 
microparticles. 
Drug release is affected by particle size. Smaller particles have larger surface 
area, therefore, most of the drug associated would be at or near the particle surface, 
leading to fast drug release. Whereas, larger particles have large cores which allow 
more  drug  to be encapsulated  and slowly  diffuse  out. Smaller  particles  also have 
greater   risk   of   aggregation   of   particles   during   storage   and   transportation   of 
nanoparticle dispersion. It is always a challenge to formulate nanoparticles with the 
smallest  size  possible  but  maximum  stability.  Polymer  degradation  can  also  be 
affected by the particle size. For instance, the rate of PLGA polymer degradation was 
found to increase with increasing particle size in vitro. It was thought that in smaller 
particles, degradation products of PLGA formed can diffuse out of the particles easily 
while in large particles,  degradation  products  are more likely  remained  within the 
polymer matrix for a longer period to cause autocatalytic degradation of the polymer 
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material. Therefore, it was hypothesized that larger particles will contribute to faster 
polymer degradation as well as the drug release. 
However,  Panyam et al prepared  PLGA particles with different size ranges 
and found that the polymer degradation rates in vitro were not substantially different 
for  different  size  particles.  Currently,  the  fastest  and  most  routine  method  of 
determining particle size is by photon correlation spectroscopy or dynamic light 
scattering. Photon-correlation spectroscopy requires the viscosity of the medium to be 
known and determines  the diameter  of the particle  by Brownian  motion  and light 
scattering  properties.  The  results  obtained  by  photon-correlation  spectroscopy  are 
usually verified by scanning or transmission electron microscopy (SEM or TEM) 
C.  Surface properties of nanoparticles: 
 
When nanoparticles are administered intravenously, they are easily recognized 
by  the  body  immune  systems,  and  are  then  cleared  by  phagocytes   from  the 
circulation.   Apart  from  the  size  of  nanoparticles,   their  surface  hydrophobicity 
determines  the amount of adsorbed  blood components,  mainly proteins (opsonins). 
This in turn influences the in-vivo fate of nanoparticles.  Binding of these opsonins 
onto the surface of nanoparticles called opsonization acts as a bridge between 
nanoparticles and phagocytes. The association of a drug to conventional carriers leads 
to modification  of the drug biodistribution  profile, as it is mainly delivered  to the 
mononuclear phagocytes system (MPS) such as liver, spleen, lungs and bone marrow. 
Indeed, once in the blood stream, surface non modified nanoparticles (conventional 
nanoparticles)  are rapidly opsonized  and massively  cleared by the macrophages  of 
MPS rich organs. Generally, it is IgG, compliment C3  components that are used for 
recognition  of  foreign  substances,  especially  foreign  macromolecules.  Hence,  to 
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increase  the  likelihood  of  the  success  in  drug  targeting  by  nanoparticles,  it  is 
necessary to minimize the opsonization and to prolong the circulation of nanoparticles 
in-vivo. This can be achieved by (a) surface coating of nanoparticles with hydrophilic 
polymers/surfactants; (b) formulation of nanoparticles with biodegradable copolymers 
with hydrophilic  segments  such as polyethylene  glycol (PEG), polyethylene  oxide, 
polyoxamer, poloxamine and polysorbate 80 (Tween 80). Studies show that PEG 
conformation  at  the  nanoparticle  surface  is of  utmost  importance  for  the  opsonin 
repelling  function  of the PEG  layer.  PEG  surfaces  in brush-like  and  intermediate 
configurations   reduced   phagocytosis   and   complement   activation   whereas   PEG 
surfaces in mushroom-like configuration were potent complement activators and 
favoured phagocytosis 2. 
The  zeta  potential  of a nanoparticle  is commonly  used  to characterize  the 
surface charge property of nanoparticles. It reflects the electrical potential of particles 
and is influenced by the composition of the particle and the medium in which it is 
dispersed. Nanoparticles with a zeta potential above (+/-) 30 mV have been shown to 
be stable in suspension, as the surface charge prevents aggregation of the particles. 
The zeta potential can also be used to determine whether a charged active material is 
encapsulated within the centre of the nanocapsule or adsorbed onto the surface. 
D.  Drug loading: 
 
Ideally, a successful nanoparticulate system should have a high drug-loading 
capacity  thereby  reduce  the  quantity  of  matrix  materials  for  administration.  Drug 
loading can be done by two methods: 
• Incorporating at the time of nanoparticles production (incorporation method) 
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• Absorbing the drug after formation of nanoparticles by incubating the carrier with a 
concentrated drug solution (adsorption /absorption technique). 
Drug loading and entrapment efficiency very much depend on the solid-state drug 
solubility  in matrix material  or polymer  (solid dissolution  or dispersion),  which is 
related   to  the  polymer   composition,   the  molecular   weight,   the  drug  polymer 
interaction and the presence of end functional groups (ester or carboxyl). The PEG 
moiety has no or little effect on drug loading. The macromolecule or protein shows 
greatest loading efficiency when it is loaded at or near its isoelectric point when it has 
minimum solubility and maximum adsorption. For small molecules, studies show the 
use of ionic interaction between the drug and matrix materials can be a very effective 
way to increase the drug loading. 
E.  Drug release: 
 
The release of active ingredients is important in case nanospheres. Much 
theoretically  possible  mechanism  may  be  considered  for  release  of  drugs  from 
carriers. 
They are 
 
1. Osmatically driven burst mechanism. 
 
2. Pore diffusion. 
 
3. Erosion or degradation of polymer. 
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Fig. 1.9: Drug delivery from (a) bulk-eroding and (b) surface-eroding   biodegradable 
 
System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.10: Mechanism of drug release from polymer. (a) Reservoir (b) Matrix 
 
To  develop  a  successful  nanoparticulate   system, both  drug release  and 
 
polymer biodegradation are important consideration factors. In general, drug release 
 
rate depends on: (1) solubility of drug; (2) desorption of the surface bound/adsorbed 
 
drug;  (3)  drug  diffusion  through  the  nanoparticle  matrix; (4)  nanoparticle  matrix 
 
erosion/degradation;    and   (5)   combination of   erosion/diffusion    process.   Thus 
 
solubility,  diffusion  and biodegradation  of the matrix  materials  govern  the release 
 
process.  In the  case  of nanospheres,  where  the  drug  is uniformly  distributed,  the 
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release  occurs  by diffusion  or erosion  of the matrix  under  sink conditions.  If the 
diffusion of the drug is faster than matrix erosion, the mechanism of release is largely 
controlled by a diffusion process. 
The rapid initial release or ‗burst‘ is mainly  attributed  to weakly  bound or 
adsorbed drug to the large surface of nanoparticles. It is evident that the method of 
incorporation has an effect on release profile. If the drug is loaded by incorporation 
method,  the system has a relatively  small burst effect and better sustained  release 
characteristics. If the nanoparticle is coated by polymer, the release is then controlled 
by  diffusion  of  the  drug  from  the  core  across  the  polymeric  membrane.  The 
membrane coating acts as a barrier to release, therefore, the solubility and diffusivity 
of drug in polymer membrane becomes determining factor in drug release. 
Drug: 
 
™ Molecular weight. 
 
™ Physicochemical properties 
 
™ Drug-carrier interaction 
 
™ Diffusion ; desorption from the surface Particles 
 
™ Type and amount of  matrix material 
 
™ Size and density of the particle 
 
™ Extent  and  nature  of  any  cross  linking;  denaturation  of  polymerization, 
presence of adjutants 
™ Drug release profile desired. 
 
™ Surface characterization such as charge and permeability. 
 
™ Degree of biodegradation, biocompatibility and toxicity. 
 
™ Total disintegration of particles 
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Environment: 
 
¾ Hydrogen ion concentration 
 
¾ Polarity 
 
¾ Ionic strength 
 
¾ Presence of enzymes 
 
¾ Temperature 
 
Furthermore release rate can also be affected by ionic interaction between the 
drug and addition of auxillary ingredients. When the drug is involved in interaction 
with auxillary ingredients to form a less water soluble complex, then the drug release 
can  be  very  slow  with  almost  no  burst  release  effect;  whereas  if the  addition  of 
auxillary ingredients e.g. addition of ethylene oxide-propylene oxide block copolymer 
(PEO-PPO)  to  chitosan,  reduces  the  interaction  of  the  model  drug  bovine  serum 
albumin (BSA) with the matrix material (chitosan) due to competitive  electrostatic 
interaction  of PEO-PPO  with  chitosan,  then  an increase  in drug  release  could  be 
observed. 
Various  methods  which can be used to study the in vitro release of the drug are: 
(1) side-by-side  diffusion cells with artificial or biological  membranes;  (2) dialysis 
bag diffusion technique; (3) reverse dialysis bag diffusion; (4) agitation followed by 
ultracentrifugation/centrifugation; (5) Ultra-filtration or centrifugal ultra-filtration 
techniques. Usually the release study is carried out by controlled agitation followed 
by centrifugation. Due to the time-consuming nature and technical difficulties 
encountered  in  the  separation  of  nanoparticles  from  release  media,  the  dialysis 
technique is generally preferred. 
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1.8. Methods for the Purification of Nanoparticles on the Laboratory Scale: 
 
(Mathlowitz Edith., 2009) 
 
Table 1.2: Purification methods of nanoparticles 
 
S.No Method Drawback 
 
1 
 
Gel filtration 
Removal of high molecular impurities 
difficult 
 
 
2 
 
 
Dialysis 
Removal high molecular weight 
impurities difficult Scaling-up 
difficult 
 
 
3 
 
 
Ultra centrifugation 
Aggregation of purities 
Time consuming process 
Scaling-up difficult 
 
 
1.9. Therapeutic Application of Nanoparticle: 
 
(Mohanraj V.J., 2006; Gadad A., 2011; Behera A.L., 2010) 
 
A) Tumor targeting using nanoparticulate delivery systems: 
 
The rationale of using nanoparticles for tumor targeting is based on following 
characteristics: 1) Nanoparticles will be able to deliver a concentrate dose of drug in 
the vicinity of the tumor targets via the enhanced permeability and retention effect or 
active  targeting  by  ligands  on  the  surface  of  nanoparticles.  2)  Nanoparticles  will 
reduce the drug exposure  of healthy  tissues by limiting  drug distribution  to target 
organ. Studies show that the polymeric composition  of nanoparticles  such as type, 
hydrophobicity  and biodegradation profile of the polymer along with the associated 
drugs molecular weight, its localization in the nanospheres and mode of incorporation 
technique, adsorption or incorporation, have a great influence on the drug distribution 
pattern in vivo. 
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The  exact   underlying   mechanism   is  not  fully   understood   but  the  bio 
distribution of nanoparticles  is rapid, within hour to 3 hours, and it likely involves 
mononuclear phagocytic system (MPS) and endocytosis/phagocytosis  process. Such 
propensity   of  MPS  for  endocytosis/   phagocytosis   of  nanoparticles   provide  an 
opportunity to effectively deliver therapeutic agents to these cells. This biodistribution 
can be of benefit for the chemotherapeutic treatment of MPS-rich organs/tissues 
localized tumors like hepatocarcinoma, hepatic metastasis arising from digestive tract 
or gynecological cancers, bronchi pulmonary tumors, primitive tumors and metastasis, 
small cell tumors, myeloma and leukaemia. 
B) Ligand attached nanoparticles: 
 
To be successful  as a drug delivery  system,  nanoparticles  must  be able to 
target tumors,  which are localized  outside  MPS-rich  organs.  In the past decade,  a 
great deal of work has been devoted to developing so called stealth particles or 
PEGylated nanoparticles, which are invisible to macrophages or phagocytes. A major 
breakthrough in the field came when the use of hydrophilic polymers (such as 
polyethylene  glycol,  poloxamines,  poloxamers,  and  polysaccharides)  to  efficiently 
coat conventional nanoparticle surface produced an opposing effect to the uptake by 
the MPS. These coatings provide a dynamic cloud of hydrophilic and neutral chains at 
the  particle   surface,   which   repel   plasma   proteins.   As  a  result,   those   coated 
nanoparticles  become invisible to MPS, therefore remained in the circulation  for a 
longer period of time and hence called as long circulating nanoparticles. 
Hydrophilic polymers can be introduced at the surface in two ways, either by 
adsorption of surfactants or by use of block or branched copolymers for production of 
nanoparticles. Studies show nanoparticles containing a coat of PEG not only have a 
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prolonged   half-life  in  the  blood  compartment   but  also  be  able  to  selectively 
extravagate  in pathological  sites such  as tumors  or inflamed  regions  with a leaky 
vasculature.  As  a  result,  such  long-circulating  nanoparticles  have  increased  the 
potential to directly target tumors located outside MPS rich regions. A size less than 
100  nm  and  a  hydrophilic  surface  are  essential  in  achieving  the  reduction  of 
opsonisation  reactions  and subsequent  clearance  by  macrophages.  Coating 
conventional  nanoparticles  with  Surfactants  or  PEG  to  obtain  a  long  circulating 
carrier has now been used as a standard strategy for drug targeting in-vivo. 
Extensive   efforts   have   been   devoted   to   achieving   active   targeting   of 
nanoparticles  in  order  to  deliver  drugs  to  the  right  targets,  based  on  molecular 
recognition processes such as ligand receptor or antigen-antibody interaction. 
Considering that fact that folate receptors are over expressed on the surface of some 
human malignant cells and the cell adhesion molecules such as selectins and integrins 
are involved in metastatic events, nanoparticles bearing specific ligands such as folate 
may be used to target ovarian carcinoma while specific peptides or carbohydrates may 
be used to target integrins and selectins 46. Targeting with small ligands appears more 
likely to succeed since they are easier to handle and manufacture.  Furthermore,  it 
could be advantageous when the active targeting ligands are used in combination with 
the long-circulating nanoparticles to maximize the likelihood of the success in active 
targeting of nanoparticles. 
C) Nanoparticles for oral delivery of peptides and proteins: 
 
Significant  advances  in  biotechnology  and  biochemistry  have  led  to  the 
discovery of a large number of bioactive molecules and vaccines based on peptides 
and proteins. Development of suitable carriers remains a challenge due to the fact that 
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bioavailability of these molecules is limited by the epithelial barriers of the 
gastrointestinal   tract  and  their  susceptibility   to  gastrointestinal   degradation   by 
digestive   enzymes.   Polymeric   nanoparticles   allow   encapsulation   of   bioactive 
molecules  and  protect  them  against  enzymatic  and  hydrolytic  degradation.  For 
instance, it has been found that insulin-loaded  nanoparticles  have preserved insulin 
activity  and  produced  blood  glucose  reduction  in  diabetic  rats  for  up  to  14  days 
following the oral administration. 
The surface area of human  mucosa  extends  to 200 times that of skin. The 
gastrointestinal  tract provides a variety of physiological  and morphological  barriers 
against protein or peptide delivery, e.g., (a) proteolytic enzymes in the gut lumen like 
pepsin,  trypsin  and  chymotrypsin;  (b)  proteolytic  enzymes  at  the  brush  border 
membrane (endopeptidases); (c) bacterial gut flora; and (d) mucus layer and epithelial 
cell lining itself. The histological architecture of the mucosa is designed to efficiently 
prevent uptake of particulate matter from the environment. One important strategy to 
overcome  the  gastrointestinal  barrier  is  to  deliver  the  drug  in  a  colloidal  carrier 
system,   such  as  nanoparticles,   which  is  capable  of  enhancing   the  interaction 
mechanisms of the drug delivery system and the epithelia cells in the GI tract. 
D) Nanoparticles for gene delivery: 
 
Polynucleotide vaccines work by delivering genes encoding relevant antigens 
to host cells where they are expressed,  producing  the antigenic  protein  within the 
vicinity  of professional  antigen presenting  cells to initiate immune  response.  Such 
vaccines produce both humoral and cell-mediated immunity because intracellular 
production of protein, as opposed to extracellular deposition, stimulates both arms of 
the immune  system.  The key ingredient  of polynucleotide  vaccines,  DNA, can be 
Acyclovir Loaded pH Sensitive Nanoparticle Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 33 
 
 
 
produced cheaply and has much better storage and handling properties than the 
ingredients of the majority of protein-based vaccines. Hence, polynucleotide vaccines 
are set to supersede many conventional vaccines particularly for immunotherapy. 
However, there are several issues related to the delivery of poly nucleotides, 
which   limit   their   application.   These   issues   include   efficient   delivery   of   the 
polynucleotide to the target cell population and its localization to the nucleus of these 
cells,  and  ensuring  that  the  integrity  of  the  polynucleotide  is  maintained  during 
delivery to the target site. Nanoparticles loaded with plasmid DNA could also serve as 
an efficient sustained release gene delivery system due to their rapid escape from the 
degradative endolysosomal compartment to the cytoplasmic compartment. Hedley et 
al. reported that following their intracellular uptake and endolysosomal escape, 
nanoparticles could release DNA at a sustained rate resulting in sustained gene 
expression. This gene delivery strategy could be applied to facilitate bone healing by 
using PLGA nanoparticles  containing  therapeutic  genes such as bone morphogenic 
protein. 
E) Nanoparticles for drug delivery in to the brain: 
 
The blood-brain barrier (BBB) is the most important factor limiting the 
development of new drugs for the central nervous system. The BBB is characterized 
by relatively  impermeable  endothelial  cells with tight junctions,  enzymatic  activity 
and  active  efflux  transport  systems.  It  effectively  prevents  the  passage  of  water 
soluble molecules from the blood circulation into the CNS, and can also reduce the 
brain concentration of lipid-soluble molecules by the function of enzymes or efflux 
pumps. Consequently, the BBB only permits selective transport of molecules that are 
essential for brain function. Strategies for nanoparticle targeting to the brain rely on 
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the presence of and nanoparticle interaction with specific receptor-mediated transport 
systems in the BBB. For example polysorbate 80 / LDL, transferring receptor binding 
antibody (such as OX26), lactoferrin, cell penetrating peptides and melanotransferrin. 
Table 1.3: Therapeutic application of nanoparticles 
 
S.No Applications Material Purpose 
 
 
 
1 
 
 
 
Cancer therapy 
 
poly(alkyl cyanoacrylates) 
nanoparticles with anti cancer 
agents, oligonucleotides 
Targeting, reduce toxicity, 
enhanced uptake of anti 
tumor agents, improved in- 
vitro and in-vivo stability 
 
 
2 
 
Intercellular 
targeting 
Poly(alkyl cyanoacrylates) poly 
ester nanoparticles with anti- 
parasitic or anti viral agents 
 
RES  for intra cellular 
infections 
 
 
3 
Prolonged 
systemic 
circulation 
Polyesters with adsorbed PEGS 
or pluronics or derivatized 
polyesters 
Prolonged systemic drug 
effects, avoid uptake by 
the RES 
 
4 
vaccine 
adjuvant 
Poly(methacrylates) 
 
nanoparticles with vaccines 
Enhanced immune 
response 
 
 
5 
 
 
Ocular delivery 
Poly (alkyl cyanoacrylates) 
nanoparticles with steroids, anti 
inflammatory agents. 
 
 
Improved retention of drug 
 
 
6 
 
 
DNA delivery 
 
DNA–alginates nanoparticles 
 
DNA-chitosan nanoparticles 
Enhanced delivery and 
significantly higher 
expression level 
 
7 
Other 
applications 
Nanoparticles with adsorbed 
enzymes 
Enzyme immunoassay , 
radio-imaging 
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1.10. Marketed Formulations of Nanoparticles:            (Nelson A Ochekpe., 2009) 
 
Table 1.4: Marketed formulations of nanoparticles 
 
 
Type of 
 
Nanostructure 
 
Trade 
name 
 
Active 
ingredient 
 
 
Indication 
 
 
Company 
 
 
 
Polymeric 
 
Nanoparticles 
 
 
 
 
Adagen 
 
 
 
Adenosine 
 
Deaminase 
Adenosine 
deaminase 
(ADA) 
enzyme 
deficiency 
 
Enzon 
Pharmaceuticals Inc., 
Bridgewater, NJ, 
USA 
  
 
Onscaspar 
 
L- 
asparaginase 
Acute 
lymphoblastic 
leukaemia 
Enzon 
Pharmaceuticals Inc., 
NJ, USA 
  
 
 
Copaxone 
 
 
Glatiramer 
 
Acetate 
Relapsing- 
remitting 
multiple 
sclerosis 
 
 
Tev Pharmaceuticals, 
Tikva, Isreal 
  
 
 
 
Macugen 
 
 
 
Pegaptanib 
 
Sodium 
All types of 
neovascular 
agerelated 
macular 
Degeneration 
Nektar Therapeutics, 
San Carlos, CA, 
USA; OSI 
Pharmaceuticals, 
Melville, NY, USA 
  
 
Pegasys 
Pegylated 
interferon alfa 
2a 
 
 
Hepatitis C 
 
Nektar Therapeutics, 
CA, USA 
  
 
 
 
Neulasta 
 
 
 
 
Pegfilgrastim 
 
 
 
 
Neutopenia 
Nektar Therapeutics, 
CA, USA; Amgen 
Inc, Thousand Oaks, 
USA. 
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1.11. Introduction to Antivirals:                              (Don A. Ballington., 2005) 
 
There are fewer medications to treat viral infections than there are for bacterial 
infections. Part of the difficulty is that antibiotics often disrupt a cellular process that 
is unique to the bacterium being treated. This allows dosing of the medication without 
causing toxicity to the patient. However, because viruses use the cellular processes of 
the host to function and replicate, medications that block the life cycle of the virus are 
often  toxic  to the patient.  Thus,  the antiviral  have been formulated  to search  and 
destroy the virus cell lodged in its host cell without interfering with the host cell's 
normal function. Antiviral are among the drugs of choice for the following conditions. 
Cytomegalovirus (CMV) retinitis 
™ genital herpes 
 
™ herpes simplex 
 
™ herpes simplex keratitis 
 
™ herpes zoster (shingles) 
 
™ influenza prophylaxis 
 
™ organ transplantation 
 
™ varicella (chicken pox) 
 
1.12. Viruses and Their Characteristics: 
 
A virus is a minute infection agent which is much smaller than a bacterium. 
Unlike a bacterium, a virus does not have all the components of a cell and thus it is 
able to replicate  only within a living host cell. Viruses,  among the most common 
infectious agents in humans, replicate by using the host cells' metabolic processes. 
A virus can infect a spectrum of cells including animal, plant, or bacteria cells. Most 
common viruses are spread by one of the following routes. 
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™ direct contact 
 
™ ingestion of contaminated food and water 
 
™ inhalation of airborne particles 
 
The individual virus particle, a virion, consists of nucleic acid (nucleoid), either 
deoxyribonucleic   acid  (RNA)  (but  not  both),  and  a  protein  shell  (capsid)  that 
surrounds and protects the nucleic acid. Depending on the virus, the capsid may be 
converted with spikes that attach to the host cell. Binding of the spikes to membrane 
receptors simulates a process whereby the cell engulfs the virus. A virus without an 
envelope covering the capsid is called a naked virus. 
1.13. Stages of Viral Infection: 
 
Within the body, viral infection takes place at the cellular level and in the following 
stages. 
1. The virus attaches to a cell receptor 
 
2. The cell membrane indents and closes around the virus (endocytosis) and thus the 
virus penetrates the cell 
3. The virus escapes into cytoplasm 
 
4. The virus uncoats, sheds its covering, and presents its DNA or RNA to cell nucleus. 
 
5. This allows the virus to convert the nuclear activity in the cell to viral activity and 
rapidly reproduce new viral particles. (It user the energy of the host cell to infect the 
cell). 
When  viruses  take  over  host  cell  nuclear  activity,  they  synthesized  viral 
enzymes, DNA, and protein, which lead to production of more virus particles. The 
infected host cells may be so damaged that it disintegrates, releasing bursts of mature 
visions are released slowly. During the release process, the virion often receives an 
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envelope,  or  capsid,  from  the  nuclear  or  the  plasma  (cell)  membrane.  All  virus- 
infected  cells have some cellular  characteristics  different  from those of uninfected 
cells.     These     differences     provide     opportunities     to     target     and     block 
viral division with medications without affecting normal cells. 
1.14. Viral Classification: 
 
Viral  infections  are  classified  in  two  ways.  The  first  classification  is  the 
duration or length of time they have been present in the body as well as their severity. 
The second classification measures the extent of the infections within the body or the 
parts of the body that are affected. 
1.14.1. Viral Duration and Severity: 
 
With  the  classification  of  duration  and  severity  there  are  three  categories: 
acute,  chronic,  and slow.  An acute viral  infection  quickly  resolves  with no latent 
infection.   Examples   include   the   common   cold,   influenza,   and   various   other 
respiratory tract infections. A chronic viral infection has a protected course with long 
periods  of  remission  interspersed   with  reappearance,   such  as  the  herpes  virus 
infection. A slow viral infection maintains a progressive course over months or years, 
with  cumulative  damage  to  body  tissue,  ultimately  ending  in  the  host's  death. 
Examples of this type of destructive viral infection include human immunodefficiency 
virus (HIV) and diseases affecting the central nervous system (CNS). 
1.14.2. Viral Infection: 
 
When  evaluating  the  extent  of  the  viral  infection,  it  must  be  determined 
whether the infection is local or generalized. A local viral infection affects tissue of a 
single system, such as the respiratory tract. A generalized viral infection is one that 
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has spread or is spreading to other tissue by way of the bloodstream or tissue of the 
 
CNS. 
 
1.15. Viral Life Cycle:                                                                        (Ilango K., 2005) 
Viral  life  cycle  varies  with  species,  but  they  all  share  a  general  petten  can  be 
sequenced as follows: 
Virus 
Adsorption 
Penetration 
Uncoating 
Transcription 
Reverse transcriptase 
Translation 
Assembly 
Release 
 
Fig. 1.11: Pathology of viral life cycle 
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1) Adsorption: Attachment of virus to the host cell. 
 
2) Penetration: Penetration of virus into the cell. 
 
3) Uncoating: The genetic material or viral genome (DNA or RNA) passes into the 
host -cell, leaving the capsid covering outside the host cell. 
4) Transcription: Production of viral mRNA from the viral genome. 
 
5) Translation:  Viral genome enters the cytoplasm or nucleo plasma and directs or 
utilizes the host nucleic acid machinery for the synthesis of new viral protein and for 
the production  of more viral genome.  The viral protein modifies the host cell and 
allows the viral genome to replicate by using host and viral enzyme. This is often the 
stage at which the cell is irreversible modified and eventually killed. 
6) Assembly of viral particle: New viral coat protein assembly into capsid and viral 
genomes. 
7) Release of the mature virus from the cell by budding process or rupture of the cell 
and repeat of the process, in fresh host cell. Since the host cell machinary is totally 
utilized for production of new visions, the normal cell function ceases at the times of 
replication. 
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General approaches for treating the virus infection by antiviral agents are: 
 
 
 
Fig. 1.12: Various classes of anti-viral agents against the virus life cycle 
a) Interference of virus attachment to the host 
b) Inhibition of virus associated enzymes 
c) Inhibition of transcription process 
d) Inhibition of translation process 
 
e) Interference with viral regulatory process 
 
f) Interference with glycosylation, phosphorylation, etc., 
g) Interference with viral assembly of viral protein 
h) Interference with release of virus from cell surface membrane. 
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Table 1.5: List of some RNA virus types together with disease that they cause 
 
RNA Viruses 
Virus Disease 
Picornaviruses Polio, Hepatitis A 
Rhinovirus Commen cold, Pneumonia 
Togavirus Rubella, Encephalitis 
Flavirus Yellow fever, Dengue fever, St.Louis encephalitis 
Bunyaviruses Encephalitis, Hemorrhagic fever 
Rhabdoviruses Vesicular stomatitis 
Myxoviruses Mumps, Measles 
Reoviruses or Rotaviruses Diarrhea 
Arenaviruses Lymphatic choriomeningitis 
Retroviruses Human immunodeficiency syndrome (HIV) 
 
 
Table 1.6: List of some DNA virus types together with disease that they cause 
 
DNA Viruses 
Virus Disease 
Herpes viruses Herpes, Cold sores 
Papovaviruses Polyoma, warts 
Adenoviruses Respiratory complications 
Poxvirus Smallpox 
Parvirus Canine distemper 
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2. LITERATURE SURVEY 
 
 
 
 
 
2.1. Literature Review: 
 
Recent advancement in nanoparticle drug delivery systems: 
 
1) Adlin jino nesalin j. et al., (2009) nanoparticles  with Flutamide using chitosan 
polymer by ionic gelation technique. Nanoparticles of different core: coat ratio were 
formulated and analyzed for total drug content, loading efficiency, particle size and in 
vitro drug release studies. From the drug release studies it was observed that 
nanoparticles prepared with chitosan in the core: coat ratio 1:4 gives better sustained 
release for about 12 hrs as compared to other formulations. 
2) Anilkumar J. Shinde. et al., (2011) was formulated nanoparticle with simvastatin. 
Simvastatin is a lipid lowering agent, and BCS class-II drug having low solubility and 
high permeability. Since simvastatin undergoes extensive first pass extraction in the 
liver,  the  availability   of  the  drug  to  the  general  circulation   is  low  (<  5%). 
Nanoparticles were prepared by precipitation-solvent deposition method using 3
2 
full 
 
factorial design. From the preliminary trials, the constraints for independent variables 
X1 (amount  of PLGA)  and X2 (amount  of Pleuronic  F-68)  have been  fixed. The 
prepared formulations were further evaluated for drug content, in vitro drug release 
pattern,  short  term  stability  and  drug  excipient  interactions.  The  application  of 
factorial design gave a statistically systematic approach for the formulation and 
optimization   of   nanoparticles   with   desired   particle   size   and   high   entrapment 
efficiency.  Drug:  polymer  ratio  and  concentration   of  stabilizer  were  found  to 
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influence  the particle  size and entrapment  efficiency  of simvastatin  loaded  PLGA 
nanoparticles.  These  results  indicate  that  simvastatin  loaded  PLGA  nanoparticles 
could be effective in sustaining drug release for a prolonged period. 
3) Arpita Bhattacharya. et al., (2003) work was focused for development by 
generalized   upgradable   bench   top   level   technology   for   nanocapsulation    of 
antineoplastic  drug  substances.  Methotrexate  was  selected  as  a  modal  drug  and 
calcium alignate was used as a coating material. A nebulizer head was so designed as 
to atomize a drug-polymer micro emulsion directly into calcium chloride cross linker 
media.  Nanocapsules  thus  formed  were  compared  with  those  produced  by  in situ 
gelling technique. Control of various process parameters resulted in the development 
of superior drug nanocapsules by pneumatic nebulisation technique with good yield. 
4)   Atmaram   P.   pawer.   et   al.,   (2009)   were   prepared   Eudragit
®
-EPO   based 
 
nanoparticle suspension of isolated andrographolide in order to increase its solubility 
and efficacy. Andrographolide nanoparticle was prepared by precipitation technique. 
The  3
2    
factorial  design  was  used  to  study  the  effect  of  Eudragit
®
-EPO   and 
Pluronic
®   
F-68  on  characteristics  of  nanoparticle  suspension.  There  was  marked 
 
increase  in  drug  dissolution  with  complete  drug  release  within  10  minutes  in 
nanoparticle  suspension  and  redispersed  nanoparticle  suspension  compare  to  pure 
drug. However, lyophilization retarded the drug release. The results were confirmed 
by histopathological studies on hepatic lesions. Thus particle engineering can we used 
to improve pharmaceutical properties of phytoconstituents. 
5) Bivash Mandal. et al., (2010) was aimed to prepare polymeric nanosuspension 
with inert polymer resin (Eudragit RL100) to the improving the availability of 
sulfacetamide at the intraocular level to combat bacterial infections. Nanosuspensions 
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were prepared by the solvent displacement method using acetone and Pluronic F108 
solution. Drug to polymer ratio was selected as formulation variable. Characterization 
of  the  nanosupension  was  performed  by  measuring  particle  size,  zeta  potential, 
Fourier Transform infrared spectroscopy  (FTIR), Differential Scanning Calorimetry 
(DSC), Powder X-Ray Diffraction (PXRD), drug entrapment efficiency and in vitro 
release. In addition,  freeze drying, redispersibility  and short term stability study at 
room  temperature   and  at  40ºC  were  performed.   The  results  indicate  that  the 
formulation of sulfacetamide in Eudragit RL100 nanosuspension could be utilized as 
potential delivery system for treating ocular bacterial infections. 
6) Debra T. Auguste. et al., (2008) were investigated pH-Sensitive poly(N,N- 
dimethylaminoethyl   methacrylate   (DMAEMA)/2-hydroxyethyl   methacrylate 
(HEMA) nanoparticles. It was prepared for the triggered release of paclitaxel within a 
tumor  microenvironment.   Tumors  exhibit  a  lower  extracellular  pH  than  normal 
tissues.  We  show  that  paclitaxel  release  from  DMAEMA/HEMA  particles  can be 
actively triggered by small, physiological changes in pH (within 0.2 to 0.6 pH units). 
Monodispersed   nanoparticles   were   synthesized   by   forming   an   O/W   emulsion 
followed by photopolymerization. Cell viability studies indicate that pHsensitive 
DMAEMA/HEMA  nanoparticles are not cytotoxic and may be used as an efficient, 
feedback-regulated drug delivery carrier. 
7)  Gambhire  Makarand.  et  al.,  (2010)  was  studied  the  preparation  and  physic- 
chemical evaluation of Rifampicin loaded poly-(lactic-co-glycolic) acid (PLGA) 
nanoparticles  as  per  3
2   
Factorial  Design  are  presented.  PLGA  (X1)  and  PVA 
(Polyvinyl  alcohol)  solution  (X2) as a stabilizing  agent were used as independent 
variables where Particle size (PS) (Y1), Entrapment Efficiency (EE) (Y2) and % Drug 
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Release    at    12
th      
hour    (REL)    (Y3)    were    taken    as    dependant    variables. 
Rifampicin nanoparticles were prepared by multiple emulsion solvent evaporation 
method.  Hence,  this  investigation  demonstrated  the  potential  of  the  experimental 
design in understanding the effect of the formulation variables on the quality of 
rifampicin nanoparticles. 
8) Gambhire M. S. et al., (2011) prepared the formulation of simvastatin (SIMVA) 
loaded  solid  lipid  nanoparticles  by  pre-emulsion  ultrasonication   technique.  The 
variables drug: lipid ratio, percentage  of lipid phase surfactant and sonication time 
were  studied  at  three  levels  and  arranged  in  a Box-behnken  design,  to  study  the 
influence  on response  variables  particle  size and % entrapment  efficiency  (%EE). 
From  the  statistical  analysis  of  data,  polynomial  equations  were  generated.  The 
physical characteristics of SIMVA-SLN were evaluated using particle size analyzer, 
differential  scanning  calorimetry  and  X-ray  diffraction.  The  in-vitro  drug  release 
study of SIMVA-SLN using modified Franz diffusion cell showed significantly low 
release of simvastatin (37.08%) than dispersion of pure drug (97.2 %). 
9) Mahendra nakarani. et al., (2010) studied about  the Itraconazole nosuspension in 
order   to  increase   the  aqueous   solubility   and  improve   its  formulation   related 
parameters,  dissolution  and hence oral bioavailability.  Itraconazole  nanosuspension 
was prepared by pearl milling technique using zirconium oxide beads as a milling 
media, poloxamer 407 as a stabilizer and gycerol as a wetting agent. Effect of various 
process  parameters  like,  stirring  time  and  ratio  of  the  beads  were  optimized  by 
keeping Drug:surfactant:milling  media (1:3:50) as a constant initially then optimized 
process  parameters  were  used  to  optimize  formulation  parameters  by  3
2   
factorial 
 
designs.  Optimized  nanosuspension  showed  a mean  particle  diameter  of  294  nm, 
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spherical shape with surface oriented surfactant molecules, which were stabilized 
formulation, high drug content, no chemical instability and no significant change in 
crystalline nature after formulation also. The in vitro dissolution profile of optimized 
formulation  compared  to pure drug and  marketed  formulation  (Canditral  Capsule) 
using 0.1N hydrochloric acid as dissolution medium showed higher drug release 
compared to the pure drug and marketed formulation. 
10) Panchaxari M Dandagi. et al., (2011) was developed nanoparticle for oral 
controlled release of clotrimazole and to improve its bioavailability. Nanoparticles of 
Clotrimazole were prepared by emulsion-solvent evaporation technique using PLGA 
as polymer. Different formulations were prepared using drug and polymer in 1:1, 1:2, 
1:3 ratios respectively. There was a striking improvement in the relative and absolute 
bioavailability of drug. The oral administration of unencapsulated drug was detected 
in various body organs such as liver, lungs and spleen up to 6 hours. In case of drug 
was found in liver, lungs, spleen, small intestine and kidney for one day. In can be 
concluded that oral administration  of clotrimazole nanoparticles from a sound basis 
for controlling drug release and improving its bioavailability. 
11) Panchaxari M Dandagi. et al., (2011) was prepared and evaluated the polymeric 
biodegradable   nanoparticles   of  Etoposide.  To  overcome  the  inherent  drawback 
associated with conventional drug delivery of Etoposide. An attempt is being made to 
design an alternative drug delivery system in form of nanoparticles. By Formulated 
Etoposide in nanoparticles using PLGA, we can reduce toxicity, enhanced therapeutic 
index and modify pharmacokinetics and tissue distribution. In the present study 
polymeric  biodegradable  nanoparticles(NPs)  of Etoposide  (ETP) were prepared  by 
modified  spontaneous  emulsification  solvent  diffusion  method  using  polylactic-co- 
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glycolic   acid   (PLGA)   as   biodegradable   matrix.   The   formulation   were   then 
characterized   with  respect  to  size  and  its  surface  morphology,   zeta  potential, 
entrapment efficiency, in-vitro drug release profile, sterility testing, stability studies 
and in vivo tissue  distribution  study.  In conclusion,  the drug loaded  nanoparticles 
showed  preferential  drug  targeting  to lungs  followed  by liver,  kidney  and spleen. 
Stability  study  indicated  that  4ºC  is  the  most  suitable  temperature  for  storage  of 
PLGA   nanoparticles.   Etoposide   loaded   nanoparticle   is   endowed   with   several 
exclusive advantages and hence holds potential for further research and clinical 
application. 
12)   Ping   Li.   et   al.,   (2008)   were   studied   the   Chitosan-alginate   (CS   /ALG) 
nanoparticles  prepared  by  ionotropic  pre-gelation  of an alginate  core  followed  by 
chitosan polyelectrolyte complexation technique. Nifedipine was chosen as a model 
drug. Morphology and structure characterization of nanoparticles were investigated by 
transmission  electron  microscope  (TEM)  and  Fourier  transform  infrared  spectra 
(FTIR), respectively. The diameter of the nanoparticles was about 20-50 nm, suitable 
for   uptake   within   the   gastrointestinal   tract   due   to   their   nanosize   range   and 
mucoadhesive  properties.  Nifedipine  released  from  chitosan–alginate  nanoparticles 
was 26.52% at pH1.5, 69.69% at pH6.8 and 56.50% at pH7.4 within 24hour. This 
suggests that the release of nifedipine from nanoparticles was pH-responsive. 
13) Rosario Pignatello. et al., (2006) study focused to improve the stability of 
cloricromene (AD6) in ophthalmic formulations and its drug availability at the ocular 
level. To this end, AD6-loaded polymeric nanoparticle suspensions were made using 
inert polymer resins (Eudragit RS100 and RL100). We modified the quasi-emulsion 
solvent  diffusion  technique  by varying  some  formulation  parameters  (the drug-to- 
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polymer   ratio,   the   total   drug   and   polymer   amount,   and   the   stirring   speed). 
The chemical  stability  of AD6  in the nanosuspensions  was assessed  by preparing 
some  formulations  using  (unbuffered)  isotonic  saline  or  a pH  7 phosphate  buffer 
solution as the dispersing medium. The obtained nanosuspensions showed mean sizes 
and  a  positive  surface  charge  (zeta-potential)   that  make  them  suitable  for  an 
ophthalmic  application;  these  properties  were  maintained  upon  storage  at 4°C  for 
several months. In vitro dissolution  tests confirmed  a modified release of the drug 
from the polymer matrixes. Nanosuspensions prepared with saline solution and no or 
lower amounts of surfactant (Tween 80) showed an enhanced stability of the ester 
drug  for several  months,  with  respect  to an AD6  aqueous  solution.  Based  on the 
technological results, AD6-loaded Eudragit Retard nanoparticle suspensions appear to 
offer promise as a means to improving the shelf life and bioavailability of this drug 
after ophthalmic application. 
14) Selvaraj. S. et al., (2010) were investigated the topical application of Acyclovir 
as eye ointment remains a concern for effective management of various ocular viral 
diseases  owing to poor ocular drug bioavailability.  Hence the study was aimed to 
develop  and  evaluate  nanosphere   colloidal  suspension   containing   Acyclovir  as 
potential   ophthalmic   drug   delivery   system.   The   Acyclovir   loaded   chitosan 
nanoparticles  were  prepared  by  ionic  gelation  of  chitosan  with  tripolyphosphate 
anions (TPP). The nanoparticles were characterised by Scanning Electron Microscopy 
(SEM), Zeta potential analyser, Differential Scanning Calorimetry (DSC) and Fourier 
Transform InfraRed (FTIR) Spectroscopy. The invitro diffusion profile of acyclovir 
from  the  nanoparticles  showed  a  sustained  release  of  the  drug  over  a  period  of 
24 hours. Kinetic release profiles of acyclovir from nanoparticles appeared to fit best 
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with Higuchi model with zero order and the non-Fickian diffusion was superior 
phenomenon.  Thus the results suggest  that Acyclovir  loaded  chitosan  nanoparticle 
suspension appears promising for effective management of ocular viral infections. 
15) Shashidhar Kerur. et al., (2009) was aimed to formulated a novel ophthalmic 
nanosuspension  (ONS), an alternative carrier system to traditional colloidal carriers 
for  controlled  release  (CR)  of  acyclovir  (ACV).  In  the  present  study,  ONS  is 
employed to avoid some of major disadvantages of colloidal carriers systems such as 
instability   in   culdesac   and   short   half   life   by   increasing   efficiency   of   drug 
encapsulation as well as by CR. A quassi-emulsion solvent evaporation method was 
used to prepare ACV loaded Eudragit RS 100 ONS with the aim of improved ocular 
bioavailability  and distribution.  The release profile revealed  from best formulation 
followed  Non-Fickian  diffusion  mechanism.  Stability  studies  showed  a  maximum 
drug content and almost similar in vitro release compared to the initial data found for 
the sample stored at 4°C. Overall, the study also revealed that ONS was capable of 
releasing the drug for a prolonged period of time and increased bioavailability. 
16)  Sivabalan   M.  et  al.,  (2011)  was  formulated   and  evaluated   chitosan  and 
Eudragit®  nanoparticles  of 5- Fluorouracil  for cancer therapy. Nanoparticles  of 5- 
Fluorouracil  were  prepared  using  chitosan  , Eudragit®  S 100,  liquid  paraffin  and 
Tween  -20  using  Emulsion  droplet  coalescence  method.  The  concentration  of the 
polymers Chitosan and Eudragit® S 100 were selected based on the results on 
preliminary  screening.  The nanoparticles  prepared  were evaluated  for morphology, 
loading efficiency, invitro release and invitro anticancer activities. The particle shape 
and  morphology  of the prepared  5-Fluorouracil  nanoparticles  were  determined  by 
SEM analysis. A franz diffusion cell was used to monitor 5-Fluorouracil release from 
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the nanoparticles.  The in-vitro  anticancer  activity  of formulated  nanoparticles  was 
carried out in Dalton-Lymphoma ascites (DLA) cells bearing mice. The formulations 
CF1, CF2, EF2 and EF3 showed good drug release from the polymer. Among the four 
formulations EF 2 (1% Chitosan & 1.5 % Eudragit® S 100) showed maximum drug 
release   in  12  hours  diffusion   study   and  good  entrapment   efficiency.   In-vitro 
anticancer study revealed that the formulated nanoparticles were found to have good 
cidal activity on cancer cells in sustained manner. 
17) Robhash Kumar Subedi. et al., (2009) were studied the Solid lipid nanoparticles 
(SLN) loaded with doxorubicin. It was prepared by solvent emulsification-diffusion 
method. Glyceryl caprate (Capmul®MCM C10) was used as lipid core, and curdlan 
as the shell material. Dimethyl sulfoxide (DMSO) was used to dissolve both lipid and 
drug. Polyethylene glycol 660 hydroxystearate (Solutol®HS15) was employed as 
surfactant. Major formulation parameters were optimized to obtain high quality 
nanoparticles.  In conclusion,  SLN with small particle size, high EE, and relatively 
high DL for doxorubicin can be obtained by this method. 
18) Suganeswari M. et al., (2011) was aimed to prepare, characterize and evaluate 
nanoparticles containing Hypolipidaemic drug (Atorvastatin calcium: D1N) 
Antihypertensive   agent   (Amlodipine   besylateD2N)   loaded   by   nanoprecipitation 
method  using  tribloere  polymeric  stabilizer  (Pluronic  F68).  Biodegradable 
nanoparticles formulated from poly (D, L-lactide-co-glycolide) (PLGA) polymers are 
being extensively  investigated  for various drug delivery applications.  Nanoparticles 
using PLGA polymers were formulated using nanoprecipitation technique, and were 
characterized for size, drug loading, and in vitro release. The Amlodipine has potency 
to  promote  the  activity  of  Atorvastatin.  Therefore,  Atorvastatin  and  Amlodipine 
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combination  was taken for this research. A biodegradable  nanoparticulate  approach 
was introduced here with a view to improving the efficacy and safety of Atorvastatin 
calcium. Particulate systems like nanoparticles have been used as a physical approach 
to alter and pharmacodynamic  properties  of various  types of drug molecules.  The 
nanoparticluate suspension of Amlodipine is to improve its absorption rate and 
therapeutic efficacy. 
19) Umasankar K. et al., (2010) were formulated flutamide nanoparticles. Flutamide 
is an oral antiandrogen drug primarily used to treat prostate cancer. The purpose of 
this research is to minimize the frequency of doses and toxicity and to improve the 
therapeutic  efficacy by formulating  flutamide nanoparticle.  Flutamide  nanoparticles 
were formulating by solvent evaporation method using Methacrylic acid copolymer 
(RL100) with three different ratios. Nanparticles were characterized by determining 
its particle size, drug entrapment  efficiency, drug release and stability studies. The 
particle  size  ranged  between  335  nm  to  620  nm.  Drug  content  was  found  of  be 
supportive to the drug release pattern. The invitro release of flutamide nanoparticles 
were carried out which exhibited a sustained release of flutamide from nanoparticles 
upto  16  hours.  The  results  showed  that  nanoparticles  were  more  beneficial  in 
providing drug delivery system. 
20) Vandana  Singh.  et al., (2010)  published  the article related  to Application  of 
nanotechnology  in  drug  delivery  system  has  opened  up  new  areas  of  research  in 
sustained  release  of  drugs.  The  nanoparticles  have  the  advantages  of  reaching 
otherwise less accessible sites in the body by escaping phagocytosis and entering tiny 
capillaries. Sustained release of the drug from the nanoparticles  could maintain the 
therapeutic    concentration    for    long    durations.    Rosiglitazone    loaded    gelatin 
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nanoparticles were prepared by two step desolvation method. The nanoparticles were 
characterized for various parameters. The results indicated that two step desolvation 
method is well suited to prepare gelatin nanoparticles and the process variables of the 
procedure can be fine tuned depending on the clinical applications. 
21) Vikas jain. et al., (2011) studies about mucoadhesive nanosuspension of 
ciprofloxacin and it was designed in order to improve the solubility, bioavailability 
and efficacy for the treatment of typhoid fever. The identity and purity of drug was 
established.  The compatibility  of drug  with  various  excipients  was ascertained  by 
FTIR techniques,  which  indicated  no interaction  between  the drug and excipients. 
Four different  formulations  were prepared  by optimizing  various  parameters  using 
different polymers like soya lecithin, pluronic F-68, polyvinyl alcohol, and 
polyvinylpyrrolidone K30. Particle size and polydispersity index were determined by 
photon   correlation   spectroscopy.   The   promising   formulations   prepared   from 
combination of soya lecithin and pluronic F68 and those based on soya lecithin alone 
were subjected to dissolution profile studies. The later formulation exhibited fast 
dissolution  rate  as  compared  to  the  former.  Thus  nanosuspension  based  on  soya 
lecithin was incorporated into hydrogels prepared using different grades of carbopol 
934 and 971 as mucoadhesive  polymers.  After 10 hours,  mucoadhesive 
nanosuspensions showed 45 to 56% release. The developed mucoadhesive 
nanosuspensions   exhibited   satisfactory   physical   stability.   The  studies   indicated 
potential of these formulations as novel gastro retentive systems. 
22) Vikram M. Pandya. et al., (2011) literature on poor water solubility and slow 
dissolution  rate  are issues  for  the  majority  of upcoming  and  existing  biologically 
active compounds. Simvastatin is poorly water-soluble drug and its bioavailability is 
Acyclovir Loaded pH Sensitive Nanoparticle Literature Survey  
 
 
very low from its crystalline form. The purpose of the present investigation  was to 
increase the solubility and dissolution rate of simvastatin by the preparation of 
nanosuspension by nanoprecipitation technique at laboratory scale. Prepared 
nanosuspension was evaluated for its particle size and in vitro dissolution study and 
characterized  by  differential  scanning  calorimetry  (DSC)  and  scanning  electron 
microscopy  (SEM).  These results  indicate  the suitability  of 2
3  
factorial  design for 
 
preparation of simvastatin loaded nanosuspension significantly improved in vitro 
dissolution rate, and thus possibly enhance fast onset of therapeutic drug effect. 
23) Yadav A V. et al., (2009) was prepared and characterized  the Eudragit E 100 
 
Nanoparticles  of Carvedilol. Nanoparticles  of Carvedilol with Eudragit E 100 were 
prepared by the nanoprecipitation method using polymeric stabilizer Poloxamer 407. 
nanoparticles of Carvedilol were obtained with high encapsulation efficiency. 
Nanoparicles   of   Carvedilol   were   obtained   with   high   encapsulation   efficiency 
(85-91%).   The  drug   release   from  the  carvedilol   nanoparticles   showed   within 
5 minutes. These studies suggest that the feasibility of formulating carvedilol-loaded 
 
Eudragit E 100 nanoparticles for the treatment of hypertension. 
 
24) Yadav S. et al., (2011) was developed the sustained release mucoadhesive 
microspheres of Acyclovir. Sodiumcarboxymethylcellulose and 
hydrxypropylmethylcellulose  were  used  as  mucoadhesive  polymers.  The 
microspheres  were  prepared  using  solvent  evaporation  technique.  The  effect  of 
variable  concentration  of polymers  on the characteristics  of the microspheres  was 
studied. The use of higher amounts of polymer significantly increased the median size 
of   the   microspheres.    The   efficiency   of   encapsulation    increased   when   the 
concentration  of polymers  was  increased.  The  poor  bioavailability  of acyclovir  is 
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attributed to short retention of its dosage form at the absorption sites. The results of 
mucoadhesion study showed better retention of Sodium CMC microspheres (8.0±0.8 
h)  in  duodenal  and  jejunum  regions  of  intestine.  Overall,  the  result  indicated 
prolonged delivery with significant improvement in oral bioavailability  of acyclovir 
from mucoadhesive microspheres due to enhanced retention in the upper GI tract. 
25)  Yiguang  Jin.  et  al.,  (2006)  studied  about  designing  of  Self-assembled  drug 
delivery systems (SADDS). It was prepared from the amphiphilic conjugates of 
hydrophilic  drugs and lipids through self-assembling  into small-scale  aggregates in 
aqueous  media.  The  outstanding  characteristic  of  SADDS  is  that  they  are  nearly 
wholly composed of amphiphilic prodrugs. The self-assembled nanoparticles (SAN) 
as one of SADDS had been prepared from the lipid derivative of acyclovir (SGSA) in 
the previous paper. They were further studied on the properties  and the in vitro/in 
vivo   behavior   in   this   paper.   The   SAN   kept   the   physical   state   stable   upon 
centrifugation  or some additives including some inorganic  salts, alkaline solutions, 
surfactants and liposomes except for HCl solution, CaCl2 solution and animal plasma. 
Autoclave  and  bath  heat  for  sterilization  hardly  influenced  the  SAN.  However, 
gamma-irradiation strongly destroyed the structure of SAN and SGSA was degraded. 
26)  Zhang  guoliang.  et  al.,  (2006)  aimed  to  improve  the  cancer-targeting  and 
selective  activity  of antineoplastic  agent [5-fluorouracil  (5-FU)].  It is a novel pH- 
responsive drug delivery system [pullulan acetate/sulfonamide (PA/SDM) conjugate] 
was synthesized by a diafiltration method. Sulfonamide was grafted to the 
hydrophobically  modified  pullulan  acetate  to enhance  the pH sensitivity  for better 
cancer-targeting delivery. 5-FU was loaded into the self-assembled nanoparticles by 
the same  method.  The drug-loaded  self-assembled  nanoparticles  were  successfully 
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obtained and characterized in terms of particle size, morphology and drug loading and 
release profile at various pHs. The results showed that the mean diameter of the self- 
assembled particles was approximately 100 nm, with uniform size and good spherical 
morphology. The nanoparticles showed good stability at pH 7.4, which is equal to that 
of the normal body fluid, but shrank and aggregated below pH 6.8, which is close to 
the pH with tumors. The loading efficiency and concentration of released 5-FU was 
monitored  at  269  nm  on  the  UV/Vis  spectrophotometer.  The  release  profile  was 
heavily pH-dependent around physiological pH, and the release rate was significantly 
enhanced under pH of 6.8. 
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2.2. DRUG PROFILE 
 
 
 
 
 
ACYCLOVIR:     (IP., 2007; Merck Index., 1997; USP., 2009; Tripathi K.D., 2004) 
 
Acyclovir is active against herpes group of virus; H. simplex type 1 is the most 
sensitive  followed  by the H. simplex  type II> varicella-zoister  =Epstein-bar  virus; 
Cytomegalovirus (CMV) is practically not affected .the prototype antiviral agent used 
to treat various types of herpes infections. Since, acyclovir was the first antiviral to be 
considered  the gold  standard  for the  treatment  of herpes  infections,  all other  anti 
herpes virus medications  are compared  to it. It is approved  for the prophylaxis  of 
herpes genitals. 
A.  Chemical name: 
 
9 – [(2 hydroxyethoxy) methyl] -9H- guanine 2-amino-1, 9-dihydro-9-[(2- 
hydroxyethoxy) methyl]-6H-purin-6-one 
B.  Structural formula: 
 
 
 
O 
HN            N 
H2N       N       
N 
 
 
CH 2OCH 2CH 2OH 
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C.  Physical properties: 
 
™ Molecular formula    : C8H11N5O3 
 
™ Molecular weight      : 225 
 
™ Description                 : White, crystalline powder, fine powder 
 
™ Odour                         : Characteristic 
 
™ Taste                           : Bitter to alkaline 
 
™ Melting point             : Melt at about 230º with decomposition (BP) 
 
: Melt at about 250º with decomposition (USP) 
 
™ Dissociation constant (pKa): 2.3, 9.2 
 
™ Solubility                    : Freely soluble in dimethyl sulphoxide; 
Slightly soluble in water; 
Very slightly in ethanol (95%); 
 
Dissolves in dilute solutions of mineral acids 
and Alkaline hydroxides. 
™ Storage                       : Store in well closed containers 
 
D.  Mode of action: 
 
Acyclovir is a synthetic analogue deoxy guanosine in which the carbohydrate moiety 
is acyclic.  The  modes  of action  of acyclovir  consist  of the following  consecutive 
mechanism: 
1.         Conversion to active acyclovir monophosphate within cells by viral thymidine 
kinase. This phosphorylation reaction occurs faster in infected cell than normal cell, 
because acyclovir is a poor substrate for the normal cell thymidine kinase. Acyclovir 
monophosphate  is further converted  in to di and triphosphate  by a normal cellular 
enzyme guanosine monophosphate kinase. 
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2.         Acyclovir  triphosphate  inhibits  viral DNA polymerase  by competing  deoxy 
guanosine triphosphate. The triphosphate drug is also incorporated in to viral DNA 
where it acts as a chain terminator,  because it has 3' - hydroxy  group, like cyclic 
sugar, 3' 5' - phosphodiester bond can be formed. It acts as suicide inhibitor because 
the terminated DNA template containing acyclovir as ligand binds irreversibly with 
DNA  polymerase  and  inactivates.  It is a drug  of  choice  in  both  prophylaxis  and 
treatment of herpes simplex virus. 
Viral thymidine kinase 
Acyclovir                                                                   Active Acyclovir monophosphate 
 
Guanosine mono 
Phosphate kinase 
 
Acyclovir diphosphate 
 
Phosphate kinase 
 
 
 
Acyclovir triphosphate 
 
 
 
 
 
Deoxy guanosine                            DNA polymerase 
triphosate                                                                             DNA Chain terminates 
 
 
 
Fig. 2.1: Mechanism of Acyclovir 
 
 
E.  Pharmacokinetics: 
 
™ Oral bioavailability                           : 15-30% 
 
™ Protein binding                                  : 9-33% 
 
™ Volume of distribution                      : 0.8 L/kg. 
 
™ Half life                                               : 2.5-3.3 hours. 
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™ Route of administration                    : Especially oral, IV, cream 5% 
 
in an   aqueous cream base and 
eye ointment. 
F.  Absorption: 
 
Acyclovir  is poorly absorbed  from the gastro intestinal  tract following  oral 
administration.  The oral bioavailability  ranges from 10 to 20% and decreases with 
increased doses. The Cmax and AUC are dose dependent and show no proportionality. 
The Cmax  for a bioavailability  ranges from 10 to 20% and decreases with increased 
doses. The Cmax and AUC are dose dependent and show no proportionality. The Cmax 
for a 200 mg dose is 0.83 µg/mL, 1.21 µg/mL for a dose of 400 mg and 1.61 µg/mL 
for a dose of 800 mg. Oral absorption is not affected by food consumption. There is 
minimal systemic absorption following topical administration of acyclovir. No drug is 
detectable in the blood or urine. Following intravenous administration  of acyclovir, 
the mean Cmax  is 9.8 µg/mL with a dose of 5 mg/kg every 8 hours and 20.7 µg/mL 
with a dose of 10 mg/kg every 8 hours. 
G.  Distribution: 
 
The volume of distribution  is 0.8 L/kg. Protein binding of acyclovir ranges 
from 9% to 33%, and distributes extensively throughout the body. The highest 
concentrations   are   in   the   kidneys,   liver   and   intestines.   Cerebro   spinal   fluid 
concentrations are about 50% that of the plasma. Acyclovir does cross the placenta. 
H.  Metabolism: 
 
Acyclovir   is   converted   to   acyclovir   monophosphate   by   virus   specific 
thymidine kinase, diphosphate by cellular guanylate kinase, and then ultimately 
converted  to  acyclovir  triphosphate   via  cellular  enzymes.  Acyclovir  undergoes 
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minimal  hepatic  metabolism   by  aldehyde  oxidase,  alcohol  dehydrogenase,   and 
aldehyde dehydrogenase to form inactive metabolites. 
I.   Excretion: 
 
Acyclovir is primarily eliminated by the kidneys via glomerular filtration and 
tubular secretion. It is found in the urine from 62% to 90% as unchanged drug and 
metabolites.  The plasma  elimination  half life of Acyclovir  ranges from 2.5 to 3.3 
hours in patients with normal renal function. 
J.   Contraindications: 
 
Hypersensitivity    to   valcyclovir,   acyclovir,   or   any   component   of   the 
formulations. 
K.  Precautions: 
 
¾ Dosage  reduction  is  recommended  when  administering  acyclovir  to 
patients with renal impairment. 
¾ Use with caution in the elderly due to decreased renal function. 
 
¾ Use with caution in patients who receive nephrotoxic drugs. 
¾ Use  caution  when  administering  via  IV  in  those  with  pre-existing 
neurologic abnormalities, serious hepatic or electrolyte abnormalities, 
or hypoxia. 
 
L.  Interactions: 
¾ Probenecid: concomitant administration of probenecid and Cimetidine 
with acyclovir  increases  the acyclovir  mean  half life and under  the 
plasma   concentration   curve,   thus   decreasing   renal   clearances   of 
 
probenecid. 
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¾ Observe caution if administration nephrotoxic drugs simultaneous. 
 
¾ Zidovudine: Acyclovir along with zidovudine causes sever drowsiness 
and lethargy. 
M. Dosage forms: 
 
¾ Intravenous infusion 
 
¾ Capsule 
 
¾ Tablet 
 
¾ Suspension 
 
¾ Topical cream 
 
¾ Topical ointment 
 
N.  Dosage limits: 
 
Capsules                                 : 200 mg 
 
Tablets                                    : 400 mg, 800 mg 
Suspension                              : 200 mg/5mL 
Powder for injection             : 500 mg, 1000 mg 
Solution for injection            : 50 mg/5mL 
Creams                                   : 5% 
Ointment                                : 5% 
 
O.  Over dosage Measures: 
 
Precipitation  of  acyclovir  in  renal  tubules  may  occur  when  the  solubility 
(2.5 mg/mL) is exceeded in the intra tubular fluid. This can be treated with hemo 
dialysis until renal function is restored. 
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P.  Commercial products of Acyclovir: 
 
Table 2.1: Commercial products of Acyclovir 
 
Trade name Preparation Dose Manufacturer 
Acivir Tablet 
Injection 
Cream (5 %) 
Ointment (3 %) 
200, 400 and 800 mg 
 
10 mL 
 
5 g 
 
5 g 
Cipla 
Acivirall DT- tablet 200 and 400 mg Finecure 
Alovir Tablet 200, 400 and 800 mg Adley 
Axovir Tablet 
 
Injection 
200, 400 and 800 mg 
 
250 and 800 mg vials 
Samarth 
Clovirax DT- tablet 
 
Cream (5 %) 
200, 400 and 800 mg 
 
5 g 
Purehealth 
Cyclovir Tablet 
 
Cream (5 %) 
200 mg 
 
5 g 
Zydus cadilla 
Herpex DT- tablet 
 
Cream (5 %) 
200 and 800 mg 
 
5 g 
Torrent 
Lovir Tablet 400 and 800 mg Eli lilly 
Ocuvir Ointment (3 % ) 5 g FDC 
Zovirax Suspension 
Ointment (3 %) 
Tablet 
400 mg/5 mL 
 
5 g 
 
200, 400 and 800 mg 
GSK 
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2.3. POLYMER PROFILE 
 
 
 
 
EUDRAGIT 
®
- EPO: 
 
™ Non-proprietary names: 
 
Ph. Eur: Basic Butylated Methacrylate Copolymer 
 
USP/NF: polymer conforms to Amino Methacrylate Copolymer - NF 
 
JPE: Aminoalkyl Methacrylate Copolymer E 
 
™ Synonyms: 
 
Eudragit
®
-EPO is a cationic copolymer based on dimethylaminoethyl 
methacrylate,    butyl   methacrylate,    methyl   methacrylate    and   acrylates/ 
dimethylaminoethyl methacrylate copolymer. 
™ Chemical/IUPAC name: 
 
Poly(butyl methacylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl 
methacrylate) 1:2:1 
™ Molecular weight: 
 
approximately  47,000 g/mol 
 
™ Structural formula: 
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™ Functional catrgory: 
 
Film former; tablet binder; tablet diluents. 
 
™ Application in pharmaceutical formulation or technology: 
 
Eudragit
®
-EPO  is used as a plain or insulating  film former; it is soluble in 
gastric fluid below pH 5. In contrast, Eudragit L, S and FS types are used as 
enteric  coating  agents  because  they  are  resistant  to gastric  fluid.  Different 
types are available that are soluble at different pH values: e.g. Eudragit L is 
soluble at pH > 6; Eudragit S and FS are soluble at pH > 7. 
™ Description: 
 
It is a white powder with a characteristic amine-like odour. 
 
 
™ Typical property: 
 
Alkili value                : 162-192 
 
Density (bulk)            : 0.390 g/cm
3
 
 
Density (tapped)        : 0.424g/cm
3
 
 
™ Flash point                 : not flammable 
 
™ Melting point             : 125°C 
 
™ Solubility: 
 
Eudragit
®
-EPO dissolves in 7 g methanol, ethanol, and isopropyl alcohol, 
acetone, ethyl acetate, methylene chloride or 1 N hydrochloric acid to give clear to 
slightlycloudy solutions. 
™ Stability and storage condition: 
 
 
Store at temperature up to 25°C (77 °F). Protect against moisture. PP box with 
 
Polyethylene inner bag. 
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Fig. 2.2: pH sensitivity of the different grade Eudragit polymers 
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2.4. EXCIPENT PROFILE 
 
 
 
 
 
PLURONIC 
® 
F-68:                                                               (Raymond C Rowe., 2003) 
™ Nonproprietary names: 
BP        : Poloxamers 
 
PhEur  : Poloxamera 
 
USPNF: Poloxamer 
 
™ Synonyms: 
 
Lutrol; Monolan; Pluronic; poloxalkol; polyethylene–propyleneglycol 
copolymer; polyoxyethylene polyoxypropylene copolymer; Supronic; Synperonic. 
™ Chemical name and CAS registry number: 
 
a-Hydro-o   hydroxypoly(oxyethylene)poly(oxypropylene)   poly(oxyethylene) 
 
block copolymer. 
 
™ Empirical formula: 
 
The  Pluronic  polyols  are  a  series  of  closely  related  block  copolymers  of 
ethylene oxide and propylene oxide conforming to the general formula 
HO(C2H4O)a(C3H6O)b(C2H4O)aH. 
™ Molecular weight: 
 
Solid 80 27 7 680–9 510 
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™ Structural formula: 
 
 
 
™ Functional category: 
 
Dispersing agent 
Emulsifying agent 
Coemulsifying agent 
Solubilising agent 
Tablet lubricant 
Wetting agent 
™ Applications in pharmaceutical formulation or technology: 
 
Pluronics  are nonionic  polyoxyethylene–polyoxypropylene  copolymers  used 
primarily in pharmaceutical  formulations as emulsifying or solubilizing agents. The 
polyoxyethylene segment is hydrophilic while the polyoxypropylene segment is 
hydrophobic.  All of the Pluronics  are chemically  similar  in composition,  differing 
only  in  the  relative  amounts  of  propylene  and  ethylene  oxides  added  during 
manufacture. Their physical and surface-active properties vary over a wide range and 
a  number  of  different  types  are  commercially  available.  Pluronics  are  used  as 
emulsifying agents in intravenous fat emulsions, and as solubilizing and stabilizing 
agents to maintain the clarity of elixirs and syrups. Pluronics  may also be used as 
wetting  agents,  in  ointments,  suppository  bases,  and  gels,  as  tablet  binders  and 
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coatings. Pluronic F-68 has also been used as an emulsifying agent for fluorocarbons 
used as artificial blood substitutes and in the preparation of solid-dispersion systems. 
More recently, Pluronics have found use in drug-delivery  systems. Therapeutically, 
Pluronic  F-6  is  administered  orally  as  a  wetting  agent  and  stool  lubricant  in  the 
treatment of constipation;  it is usually used in combination  with a laxative such as 
danthron. Pluronics may also be used therapeutically  as wetting agents in eye-drop 
formulations, in the treatment of kidney stones, and as skin-wound cleansers. Pluronic 
338 and 407 are used in solutions for contact lens care. 
 
Table 2.2: Applications of pluronic in pharmaceutical formulation 
 
S.NO. USE CONCENTRATION 
1 For emulsifier 0.3 
2 Flavour solubilizer 0.3 
3 Fluorocarbon emulsifier 2.5 
4 Gelling agent 15-50 
5 Spreading agent 1 
6 Stabilizing agent 1-5 
7 Suppository base 4-6 or 90 
8 Tablet coating 10 
9 Tablet excipient 5-10 
10 Wetting agent 0.01-5 
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™ Descriptions: 
 
Pluronics generally occur as white, waxy, free-flowing prilled granules, or as 
cast  solids.  They  are  practically  odorless  and  tasteless.  At  room  temperature, 
Pluronic 124 occurs as a colorless liquid. 
™ Typical properties: 
 
Acidity/alkalinity        : pH = 5.0-7.4 for a 2.5% w/v aqueous solution. 
 
Cloud poin                  : >1008C for a 1% w/v aqueous solution, and a 10% 
 
w/v Aqueous solution of Pluronic F-68      . 
 
Density                         : 1.06 g / cm3 at 258ºC. Flowability                  
: solid Pluronics are free flowing. HLB value                   : 
0.5-30; 29 for Pluronic F-68           . Melting point              : 
52–578ºC for Pluronic F-68            . 
™ Moisture content: 
 
Pluronics  generally  contain  less than 0.5% w/w water and are hygroscopic 
only at relative humidity greater than 80%. 
™ Solubility: solubility varies according to the Pluronic type. 
 
Freely soluable in ethanol, 
Freely soluable in water. 
™ Surface tension: 
 
19.8mN/m (19.8 dynes/cm) for a 0.1% w/v aqueous Pluronic F-68 solution at 
 
258ºC. 
 
™ Viscosity (dynamic): 
 
1000 mPa s (1000 cP) as a melt at 778C for Pluronic F-68. 
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™ Stability and storage: 
 
Conditions Pluronics are stable materials. Aqueous solutions are stable in the 
presence of acids, alkalis, and metal ions. However, aqueous solutions support mold 
growth. The bulk material should be stored in a well-closed container in a cool, dry 
place. 
™ Incompatibilities: 
 
Depending on the relative concentrations, Pluronic F-68 is incompatible with 
phenols and parabens. 
™ Method of manufacture: 
 
Pluronic polymers are prepared by reacting propylene oxide with propylene 
glycol to form polyoxypropylene  glycol. Ethylene oxide is then added to form the 
block copolymer. 
™ Safeties: 
 
Pluronics are used in a variety of oral, parenteral, and topical pharmaceutical 
formulations   and  are  generally  regarded  as  nontoxic  and  nonirritant  materials. 
Pluronics  are not metabolized  in the body. Animal toxicity studies, with dogs and 
rabbits, have shown Pluronics to be nonirritating and nonsensitizing when applied in 
5% w/v and 10% w/v concentration to the eyes, gums, and skin. In a 14-day study of 
intravenous  administration  at concentrations  up to 0.5 g/kg/day to rabbits, no overt 
adverse effects were noted. A similar study with dogs also showed no adverse effects 
at dosage levels up to 0.5 g/kg/day. In a longerterm study, rats fed 3% w/w or 5% w/w 
of Pluronic in food for up to 2 years did not exhibit any significant  symptoms  of 
toxicity. However, rats receiving  7.5% w/w of Pluronic in their diet showed some 
decrease  in  growth  rate.  No  hemolysis  of  human  blood  cells  was  observed  over 
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18 hours at 258ºC, with 0.001–10%  w/v Pluronic solutions.  Acute animal toxicity 
data for Pluronic F-68. 
™ Handling precautions: 
 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection and gloves are recommended. 
™ Regulatory statuses: 
 
Included  in the FDA Inactive Ingredients  Guide (IV injections;  inhalations, 
ophthalmic preparations; oral powders, solutions, suspensions, and syrups; topical 
preparations). Included in nonparenteral medicines licensed in the UK. Included in the 
Canadian List of Acceptable Non-medicinal Ingredients. 
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3. AIM AND OBJECTIVE 
 
 
 
 
Herpes simplex virus (HSV) is a member of family of herpes viridae, a DNA 
virus. There are two types of Herpes Simplex Viruses (HSV). viz HSV type 1 and type 2. 
HSV type 1 is the herpes virus that is usually responsible for cold sores of the mouth, the 
so called ―fever blisters‖. HSV type 2 is the one that most commonly causes genital 
herpes. The infection causes painful sores on the genitals in both men and women. 
Herpes sores provide a way for HIV to get past the body‘s immune defenses and make it 
easier to get HIV infection. A recent study found that people with HSV had three times 
the risk of becoming infected with HIV as compared to people without HSV. Currently 
the treatments available for herpes simplex are conventional tablets and topical gel for 
application on outbreaks. The drugs that are commonly used for herpes simplex are 
Acyclovir, Valaclovir and Famciclovir. 
Acyclovir, the first agent to be licensed for the treatment of herpes simplex virus 
infections, is the most widely used drug for infections such as cutaneous herpes, genital 
herpes, chicken pox, varicella zoster infections. Acyclovir is currently marketed as 
capsules (200 mg), tablets (200, 400 and 800 mg) and topical ointment. Oral acyclovir is 
mostly used as 200 mg tablets, five times a day. In addition, long term administration of 
acyclovir (6 month or longer) is required in immune compromised to patient with 
relapsing herpes simplex infection. The presently available conventional therapy is 
associated with a number of drawbacks such as highly variable absorption and low 
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bioavailability (10–20%) after oral administration. Furthermore, with increase in dose, 
there is decrease in bioavailability. Moreover, because the mean plasma half life of the 
drug is 2.5 hours, five times a day administration is required. In order to make oral 
therapy of acyclovir more patients compliant there is a need of using different approaches 
like matrix tablets, nanoparticle and polymeric films. 
The  main  problem  with  the  therapeutic  effectiveness  of  acyclovir  is  its 
absorption which is highly variable and dose dependent thus reducing the bioavailability 
to 10–20%. Acyclovir is soluble in acidic pH and is predominantly absorbed from upper 
gastro intestinal tract (GIT) to duodenum to jejunum regions. There are indications of its 
active absorption from the duodenum and jejunum regions of GIT. 
The inherent shortcomings of conventional drug delivery and the potential of 
nanoparticle as drug delivery systems have offered tremendous scope for researchers in 
this field and are fast moving from concept to reality. Nanoparticle may be used for oral 
administration of gut-labile drugs or those with low aqueous solubility. These colloidal 
carriers have the ability to cross the mucosal barrier as such. In addition to the potential 
for enhancing drug bioavailability via particle uptake mechanisms, nanoparticulate oral 
delivery systems also have slower transit times than larger dosage forms increasing the 
local concentration gradient across absorptive cells, thereby enhancing local and systemic 
delivery  of  both  free  and  bound  drugs  across  the  gut.  These  colloidal  carriers  are 
expected to develop adhesive interactions within the mucosa and remain in the 
gastrointestinal tract, while protecting the entrapped drug from enzymatic degradation, 
until the release of the loaded drug or their absorption in an intact particulate form. 
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The purpose of this work was to develop Eudragit
®  
EPO based nanoparticle 
suspension of acyclovir in order to increase its solubility and efficacy. The nanoparticle 
suspension was prepared by nanoprecipitation technique. The 3
2  
factorial designs were 
used to study the effect of Eudragit
®  
EPO and Pluronic
®  
F-68 on characteristics of 
nanoparticle  suspension  of  Acyclovir.  The  optimized  formulation  was  subjected  to 
lyophilization. The lyophilized nanoparticle suspension and the redispersed lyophilized 
nanoparticle suspension were characterized by particle size, drug content, entrapment 
efficiency, FTIR, DSC, SEM,   in-vitro drug release, Kinetic drug release and stability 
studies. 
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5. MATERIALS AND EQUIPMENTS 
 
 
5.1: Materials Used: 
 
Table 5.1: List of Polymers and Excipients with source 
 
S.No. Ingredients Supplier 
 
1 
 
Acyclovir 
Ajanta pharmaceutical limited, 
Mumbai. 
 
2 
 
Eudragit
® 
-EPO 
Dr. Reddys pharmaceuticals limited, 
Mumbai. 
3 Pluronic F-68 S d fine-chem limited, Mumbai. 
4 Dialysis bag Hi-media laboratories, Mumbai. 
5 Hydrochloric acid S d fine-chem. limited, Mumbai. 
6 Methanol Qualigens fine chemicals, Mumbai. 
7 Ethanol (95%) S d fine-chem limited, Mumbai. 
 
8 
Potassium dihydrogen 
orthophosphate 
 
Fischer scientific chemicals, Mumbai. 
9 Acetone Fischer scientific chemicals, Mumbai. 
10 Sodium hydroxide Fischer scientific chemicals, Mumbai. 
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5.2: Equipments Used: 
 
Table 5.2:  List of Equipments with model/make 
 
S.No Equipments Model/ Make 
1 Electronic balance Shimadzu BL-220H. 
2 Sonicator 2200MH, Soltech srl,  Soluzioni 
 
Tecnologirhe, Milano, Italy. 
3 Magnetic stirrer 1-MLH, remi equipments limited, 
vasai. 
4 Digital pH meter Elico scientifics-L1610, Mumbai. 
5 UV spectrophotometer Shimadzu-1700 Pharmaspec UV- 
VISIBLE spectrophotometer. 
6 FTIR spectrophotometer Shimadzu S4008. 
7 Differential scanning calorimeter Shimadzu DSC 60 with DTA, Japan. 
8 Micro ultra centrifuge Remi equipments limited, vasai. 
9 Freeze drying apparatus Lyostar, S.P biotech limited. 
11 Scanning electron microscope SEM, JSM-6360LV scanning 
microscope Tokyo, Japan. 
12 Zeta potential Malveran instruments, Malvern, UK. 
13 Humidity chamber Labtech. 
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6. PREFPRMULATION STUDIES 
 
 
 
 
Preformulation Study:                                                                            (Jens T., 2000) 
 
Before the formulation of a product should be investigation of physical and 
chemical  properties  of a drug substance  alone to effective,  stable and safe dosage 
form. It is the first step in rational development of dosage form. 
6.1. Identification of Drug: 
 
The preliminary studies were carried out by testing of different physical and 
chemical properties of drug as follows. 
6.1.1. Organoleptic Properties of Drug:                                       (Lachman L., 1991) 
 
The Organoleptic properties like physical state, color, taste, odor etc., of the 
drug was reported with help of the descriptive terminology. It helps to identify the 
drug. 
6.1.2. Melting Point:                                                                                       (IP., 2007) 
 
It is the easy way to identify the drug. The melting point of acyclovir was 
tested by use of a laboratory  melting point apparatus with capillary tube method a 
procedure given in the Indian Pharmacopeia 2007. 
6.1.3. Solubility Profile:                                                                                  (IP., 2007) 
 
It is important  to know about solubility  characteristic  of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
response.   The   solubility   of   drug   was   recorded   by   using   various   descriptive 
terminology specified in Indian pharmacopoeia, 2007. 
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Table 6.1: Description of solubility 
 
Descriptive term Parts of solvent required for 1 part of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble Greater than or equal to 10,000 
 
 
6.1.4. UV Spectroscopy (λ max):                                               (Kuchekar B. S., 2006) 
 
The  absorption  maximum  of  the  standard  solution  was  scanned  between 
 
200- 400 nm regions on Shimadzu-1700 Pharmaspec UV-visible spectrophotometer. 
The absorption maximum obtained with the substance being examined corresponds in 
position and relative intensity to those in the reference spectrum. 
6.1.4.1. Development of Standard Curve of Acyclovir in Distilled Water: 
 
(Kuchekar B. S., 2006) 
 
Preparation of Stock Solution of Acyclovir in Distilled Water: 
 
Weighed accurately about 100 mg of Acyclovir was dissolved in little quantity 
of  distilled  water  and  volume  was  adjusted  to  100  ml  with  the  same  to  prepare 
standard solution having concentration of 1000 µg/ml. From this solution, pipette out 
10 ml and made up to 100 ml with distilled water to produce 100 µg/ml. 
 
Procedure: 
 
From  the  stock  solution,  aliquots  of  0.4,  0.8,  1.2,  1.6  and  2  ml  were 
transferred  to 10 ml volumetric  flasks  and final volume  was made to 10 ml with 
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distilled  water  to  get  4  to  20  µg/ml.  Absorbance  values  of  these  solutions  were 
measured  against  blank  (Distilled  water)  at  252  nm  using  UV-visible 
spectrophotometer. 
6.1.4.2. Development of Standard Curve of Acyclovir in 0.1N HCl: 
Preparation of 0.1N HCl: 
0.1N HCl was prepared according to I.P. 1996. Accurately 8.5 ml of HCl was 
taken and diluted with freshly prepared distilled water to produce 1000 ml. 
Preparation of Stock Solution of Acyclovir in 0.1N HCl: 
Weighed accurately about 100 mg of Acyclovir was dissolved in little quantity 
of 0.1N HCl and volume was adjusted to 100 ml with the same to prepare standard 
solution having concentration  of 1000 µg/ml. From this solution, pipette out 10 ml 
and made up to 100 ml with 0.1N HCl to produce 100 µg/ml. 
Procedure: 
 
From the stock solution, aliquots of 0.4, 0.8, 1.2, 1.6 and 2 ml were transferred 
to 10 ml volumetric flasks and final volume was made to 10 ml with 0.1N HCl to get 
4 to 20 µg/ ml. Absorbance values of these solutions were measured against blank 
 
(0.1N HCl) at 255 nm using UV-visible spectrophotometer. 
 
6.1.4.3.  Development  of  Standard  Curve  of  Acyclovir  in  pH  7.4  Phosphate 
 
Buffer: 
 
Preparation of 0.2M Potassium Dihydrogen Phosphate: 
 
Dissolved 27.218 gm of potassium dihydrogen phosphate in water and made 
up to 1000 ml. 
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Preparation of 0.2M Sodium Hydroxide: 
 
Dissolved 8 gm of sodium hydroxide pellets in distilled water and made up to 
 
1000 ml. 
 
Preparation of Phosphate Buffer pH 7.4: 
 
Phosphate buffer pH 7.4 was prepared according to I.P. 2007. A quantity of 50 
ml of 0.2M potassium dihydrogen phosphate and 39.1 ml of 0.2M sodium hydroxide 
was diluted with freshly prepared distilled water to produce 200 ml. 
Preparation of Stock Solution of Acyclovir in pH 7.4 Phosphate Buffer: 
 
Weighed accurately about 100 mg of Acyclovir was dissolved in little quantity 
of pH 7.4 phosphate  buffer and volume was adjusted  to 100 ml with the same to 
prepare standard  solution  having concentration  of 1000 µg/ml. From this solution, 
pipette out 10 ml and made up to 100 ml with pH 7.4 phosphate buffer to produce 100 
µg/ml. 
 
Procedure: 
 
From  the  stock  solution,  aliquots  of  0.4,  0.8,  1.2,  1.6  and  2  ml  were 
transferred to 10 ml volumetric flasks and final volume was made to 10 ml with pH 
7.4 phosphate buffer to get 4 to 20 µg/ml. Absorbance values of these solutions were 
measured against blank (Phosphate Buffer pH 7.4) at 253 nm using UV-visible 
spectrophotometer. 
6.1.5. Quantification of Drug: 
 
Accurately weighed 100 mg of Acyclovir was dissolved in little quantity of 
pH 7.4 phosphate buffer and volume was adjusted to 100 ml with the same to prepare 
standard solution having concentration of 1000 µg/ml. From this solution, pipette out 
10 ml and made up to 100 ml with pH 7.4 phosphate buffer to produce 100 µg/ml. 
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From the above solution, aliquots of 2 ml were transferred to 10 ml volumetric flasks 
and  final  volume  was  made  to 10  ml with  pH  7.4 phosphate  buffer.  Absorbance 
values of these solutions were measured against blank (pH 7.4 Phosphate Buffer) at 
253 nm using Shimadzu-1700 Pharmaspec UV-visible spectrophotometer. The 
percentage  purity  of drug was calculated  by using calibration  graph method  (least 
square method). 
6.1.6. FTIR Spectroscopy:                                                                 (selvaraj S., 2010) 
 
The infrared spectrum was generally  used as an identification  parameter  to 
know  the  chemical  structure  of  drugs.  The  FTIR  spectrophotometer  was  used  to 
record the FTIR spectrum of acyclovir. A small quantity of sample was mixed with 
sufficient  potassium  bromide  and  compressed  into  a pellet  by applying  a 10 tons 
pressure with help of a hand operated press. This pellet was kept in a sample holder 
and scanned from 4000 to 400 cm
-1
 
 
6.1.7. Loss on Drying:                                                                          (IP., 2007) 
 
Loss on drying is the loss of weight expressed as percentage  w/w resulting 
from water and volatile  matter of any kind that can be driven off under specified 
condition. The accurately weighed 1gm of sample was transferred in glass-stoppered, 
shallow weighing bottle and accurately weighed the bottle. The bottle was transferred 
in oven and substance was dried at 105°C for 3 hours. The bottle was removed from 
oven and reweighed; loss on drying was calculated by following equation, 
Initial weight of substance - Final weight of substance 
LOD=                                                                                                                ×100 
Initial weight of substance 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FORMULATION OF 
 
pH SENSITIVE 
NANOPARTICLE 
Acyclovir Loaded pH Sensitive Nanoparticle Formulation of Nanoparticle 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 85 
 
 
2 
 
 
 
 
 
7.  FORMULATION OF P
H 
SENSITIVE NANOPARTICLE 
 
 
 
 
7.1. Formulation Designing by 3
2 
Factorial Designing Technique: 
(Bothiraja C., 2009) 
A prior knowledge and understanding  of the process and the variable under 
investigation  led to preliminary  experiments.  Based on the preliminary  data, the 3
2 
factorial  design  was  adopted  to  optimize  the  amount  of  Eudragit
®
-EPO  (x1)  and 
 
pluronic
®  
F-68 (x2) identify the independent variable affecting the drug content and 
the  percentage  drug  encapsulation  efficiency  (dependent  variable).  The  response 
surfaces of the obtained result were also plotted. The coded and the actual values of 
the experimental design are given in Table 7.1. The data analysis of values obtained 
from various batches for drug content and entrapment efficiency were subjected to 
multiple regression analysis using PCP dissolution software the equation fitted was 
 
Y: β0 + β1 X1 + β2 X2 + β11 X1
2 
+ β22 X 
2
 + β12 X 1X2 
 
 
Where y is the measured response; X is the level of factors; β is the coefficient 
computed from the responses of the formulations. 
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Table   7.1:   Independent   variables   and   their   selected   levels   for   nanoparticles 
 
formulation 
 
 
 
 
 
 
S. No. 
 
 
 
Independent 
variable factor 
Levels used 
Lower (-1) 
(mg) 
Middle (0) 
(mg) 
Upper (+1) 
(mg) 
1 Eudragit®-EPO 100 150 200 
2 Pluronic F-68 25 50 100 
 
 
Table 7.2: Formulation of Acyclovir loaded pH sensitive nanoparticle using 
 
3
2 
full factorial design 
 
 
 
 
S.No 
 
 
 
Batch code 
Variable level in code form 
X1 X2 
1 F1 -1 -1 
2 F2 -1 0 
3 F3 -1 +1 
4 F4 0 -1 
5 F5 0 0 
6 F6 0 +1 
7 F7 +1 -1 
8 F8 +1 0 
9 F9 +1 +1 
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7.2: Preparation of pH Sensitive Nanoparticle Suspension: 
 
(Bothiraja C., 2009; Atmaram P. Pawer., 2011) 
 
Nanoparticle   suspension  of  acyclovir  was  prepared  by  nanoprecipitation 
method. Acyclovir 100 mg and specific amount of Eudragit
®
-EPO were dissolved in 
15  ml  of  methanol.  The  organic  solution  was  quickly  injected  to 30  ml  aqueous 
solution containing pluronic
® 
F-68 under stirring at 2000 rpm. Stirring was continued 
for 2 hours at 40
0
C for complete evaporation of methanol. The volume was adjusted 
up to 40 ml with aqueous solution of 200 mg of HPMC K-15 to obtain a nanoparticle 
suspension. The optimized nanoparticle suspension was lyophilized at – 420C for 72 
hours and which was also redispersed in water to get aqueous nanoparticle suspension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure7.1: Preparation of pH sensitive nanoparticle 
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8. CHARACTERIZATION OF NANOPARTICLE 
 
 
 
8.1. Particle Size Analysis:                                                              (Yadav A.V., 2009) 
 
Particle  size  analysis  of nanoparticle  was  performed  by  photon  correlation 
spectroscopy (PCS). This technique yields the mean particle diameter and particle size 
distribution.  Samples were analyzed using Mastersizer  2000 (Malvern  Instruments, 
Malvern, UK), which allows sample measurement the range of 0.020 – 2000.00 µm. 
Polydispersity was determined according to the equation: 
 
 
Polydispersity = 
D (0.9) – D (0.1) 
 
D (0.5) 
 
Where  D (0.9) corresponds  to particle  size immediately  above  90% of the 
sample, D (0.5) corresponds  to particle size immediately  above 5% of the sample, 
D (0.1) corresponds to particle size immediately above 10% of the sample. 
 
8.2. Estimation of Drug Content:                               (Panchaxari M Dandagi., 2011) 
 
 
The nanoparticle suspension was weighed accurately (equivalent to 25 mg) of 
the acyclovir nanoparticle suspension was diluted with 0.1N HCl and the drug content 
were estimated by using UV -Visible spectrophotometer (Shimadzu UV-1700)  at 253 
nm against blank solvent system. 
Amount of drug found 
Percentage drug content =                                                  × 100 
Label claim 
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8.3. Estimation of Entrapment Efficiency:                                      (Selvaraj S., 2010) 
The entrapment efficiency of the prepared formulation was determined by the 
concentration  of  free  drug  in  the  dispersion  medium.  The  entrapment  drug  was 
determined   by  taking   10  ml  of  formulation   the  nanoparticle   suspension   was 
centrifuged  for 2 hours at 14000 rpm. The supernatant  was separated  and filtered 
through 0.45μm illipore (Millipore filter). The filtrate was diluted with 0.1N HCl and 
measured specrophotometrically  (Shimadzu UV-1700) the amount of free drug was 
determined  in filtered drug was determined.  Initial drug –free drug the entrapment 
efficiency was calculated using the following equation. 
 
W initial drug – W free drug 
Percentage drug entrapment efficiency =                                                            × 100 
W initial drug 
 
8.4. Statistical Analysis:                     (Bothiraja C., 2009; Atmaram P. Pawer., 2011) 
A prior knowledge and understanding  of the process and the variable under 
investigation  led to preliminary  experiments.  Based on the preliminary  data, the 3
2 
factorial  design  was  adopted  to  optimize  the  amount  of  Eudragit
®
-EPO  (x1)  and 
Pluronic
®  
F-68 (x2) identify the independent variable affecting the drug content and 
the  percentage  drug  encapsulation  efficiency  (dependent  variable).  The  response 
surfaces of the obtained result were also plotted. The data analysis of values obtained 
from various batches for drug content and encapsulation efficiency were subjected to 
multiple regression analysis using PCP dissolution software the equation fitted was 
 
Y: β0 + β1 X1 + β2 X2 + β11 X1
2 
+ β22 X 
2
 
 
+ β12 X 1X2    ….1 
 
Where  y is the  measured  response;  X is the level  of factors;  β is the coefficient 
computed from the responses of the formulations. 
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8.5. Fourier Transform Infra Red Spectroscopy (FTIR):            (Selvaraj S., 2010) 
The   FTIR   spectra   of   Acyclovir,   Eudragit
®
-EPO   and   Acyclovir   loaded 
Eudragit
®
-EPO nanoparticles were determined by using Shimadzu S4008 model. The 
pellets  were  prepared  by  gently  mixing  of  1mg  sample  with  200  mg  potassium 
bromide at high compaction pressure. A base line correction was made using dried 
potassium  bromide  and  the  spectra  of  dried  mixture  of  drug  and  polymers  were 
recorded. Thus the prepared pellet was scanned at a resolution of from 4000 cm 
-1 
to 
400 cm 
-1
. 
 
8.6. Differential Scanning Calorimetry Analysis (DSC): (Vikram M Pandya., 2011) 
Differential scanning calorimetry (DSC) are one of the most powerful analysis 
technique which offering the possible of detecting chemical interaction between drug 
and  polymer.  The  differential  scanning  calorimetry  of  thermograms  of Acyclovir, 
Eudragit
®
-EPO,  and lyophilized nanoparticle suspension were obtained using DSC- 
 
Shimadzu 60 with TDA trend line software. 
 
8.7. Scanning Electron Microscopy (SEM) Analysis:                 (Anilkumar J., 2011) 
The morphology  of nanoparticle  was examined  by using scanning  electron 
microscopy    (SEM,   JSM-6360LV    scanning    microscope    Tokyo,   Japan).   The 
nanoparticle  formulation  was mounted  on metal stubs using double-sided  tape and 
coated  with  a  150  A
0   
layer  of  gold  under  vacuum.  Stubs  were  visualized  under 
 
scanning  electron  microscope.   SEM  has  been  used  to  determine  particle  size 
distribution, surface topography, texture and examine the morphology of fractured or 
sectioned surface. 
Acyclovir Loaded pH Sensitive Nanoparticle Characterization of Nanoparticle 
Adhiparasakthi college of pharmacy, Melmaruvathur. Page 91 
 
 
 
8.8. Zeta Potential Measurement:                                                   (Vikas Jain., 2009) 
The zeta potential was determined by (Malvern Instruments, Malveran UK). It 
is a  measure  of  electric  charge  at  the  surface  of particles  indicating  the  physical 
stability of dispersive systems. The zeta potential values higher than 30 mV indicate 
long term electrostatic stability of aqueous dispersions. The analysis was performed 
using the clear disposable zeta cell, in distilled water at 20 V/cm of field strength. All 
measurements were done in triplicate. 
8.9. In-Vitro Drug Release Study:                            (Panchaxari M Dandagi., 2011) 
 
The in-vitro drug release of the nanoparticle suspension was studies by using 
dialysis method the formulation equivalent to 10 mg of acyclovir were placed in a 
dialysis  bag.  The  dialysis  bag  was  suspended  in  a  beaker  containing  100  ml  of 
phosphate buffer pH 7.4 on a magnetic stirrer at 100 rpm, with temperature adjusted 
to 37±0.5°C at selected time interval sample was removed and replaced with fresh 
medium.  The  sample  was  filtered  through  0.45μm  Millipore  (Millipore  filter)  the 
samples were analyzed for drug release by measuring absorbance 252 nm using UV 
visible spectrophotometer (Shimadzu UV-1700). 
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Figure 8.1: In-vitro drug release of pH sensitive nanoparticle 
 
8.10. Kinetics of In-Vitro Drug Release:                                         (Amitava G., 2009) 
 
¾   Zero order: 
 
C = K0t 
 
Where    K0 - is the zero-order rate constant expressed in units of concentration/time 
 
t -is the time in h. 
 
¾   First order:  
 
LogC = LogC0 – Kt / 2.303 
 
 
Where   C0 - is the initial concentration of drug, 
K - is the first order constant 
t - is the time in h. 
 
¾   Higuchi: 
 
 
 
Qt = Kt
1/2
 
 
Where   Qt - is the amount of the release drug in time t, 
K- is the kinetic constant and t- is time in h. 
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¾   Korsmeyer Peppas:  
 
Mt / M∞ = Kt n 
 
 
Where Mt - represents amount of the released drug at time t, 
 
M∞- is the overall amount of the drug (whole dose) released after 12 h 
 
K- is the diffusional characteristic of drug/polymer system constant 
 
n- is a diffusional exponent that characterizes the mechanism of release of drug. 
 
Table 8.1: Diffusion exponent and solute release mechanism 
 
Diffusion exponent (n) Overall solute diffusion mechanism 
< 0.5 Quasi-Fickian diffusion 
0.5 Fickian diffusion 
0.5 < n < 1.0 Anomalous (non-Fickian) diffusion 
1.0 Case-II transport 
> 1.0 Super case-II transport 
 
 
8.11. Stability Study: 
 
(Guru Prasad Mohanda., 2006; Rosario Pingnatello., 2006; IP., 2007) 
A pharmaceutical product needs to be physically, chemically, therapeutically 
toxicologically    and   microbiologically    stable   throughout    its   shelf   life.   The 
pharmaceutical companies do stability testing for estimating the shelf life and based 
on this the expiry data is given for the product. 
 
The real time studies (Long term testing) at recommended storage condition 
are ideal method for predicting shelf life. Often the studies are designed to increase 
the rate of chemical degradation  or physical change of pharmaceutical  products by 
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using exaggerated storage conditions. This is known as accelerated stability testing. 
The pharmaceutical products are subjected to higher temperature and humidity 
conditions for accelerating the degradation. However, the results of accelerated testing 
are not always predictive of physical changes and potency. 
The pharmacopeia  specifies  certain  storage  conditions.  The following  table 
gives the details as specified in Indian pharmacopeia: 
Table 8.2: Storage condition of pharmaceutical product 
 
Storage condition Meaning 
Cold Any temperature not exceeding 8ºC (2-8ºC) 
Cool Any temperature not between 8-25ºC 
Warm Any temperature not between 30-40ºC 
Excessive heat Any temperature not above 40ºC) 
 
¾   Procedure: 
 
 
The physical stability of the nanoparticle formulation F6 was evaluated after 
storage for 3 months at 4ºC ±1ºC and 25ºC ±2ºC/65% ±5% relative humidity. The 
nanoparticle  were  stored  in  screw  capped  amber-glass  bottles  and  placed  in  a 
humidity  control  oven.  Physical  instability   like  change  in  appearance,   settling 
behavior  was  observed.  The  samples  were  withdrawn  and  analyzed  for  its  drug 
content, drug entrapment efficiency and in-vitro drug release. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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9. RESULTS AND DISCUSSION 
 
 
 
9.1. Identification of Drug: 
 
9.1.1. Organoleptic Properties: 
 
Physical state :  Fine powder 
 
Colour             :  A white fine powder 
 
Odour              :  Cheracteristic 
 
Taste               :   Bitter to alkaline 
 
9.1.2. Melting Point: 
 
Melting   point   of   Acyclovir   was   found   to   be   256.6   ±1.15
0
C   with 
decomposition. The official melting point range for Acyclovir is between 256-258°C. 
Hence, results were complied the limits specified in official Book. 
9.1.3. Solubility Profile: 
 
Table 9.1: Solubility of Acyclovir in various solvents 
 
 
 
Name of solvent 
Parts of solvent required 
per part of solute 
 
Solubility 
Dilute HCl 11 Soluble 
Water 145 Slightly soluble 
Alcohol 1000 Sparingly soluble 
Acetone More than 1000 Insoluble 
The results were complied with official solubility of Acyclovir (IP 2007) 
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9.1.4. UV Spectroscopy (λ max): 
 
9.1.4.1. Determination of λ max of Acyclovir by using Distilled Water: 
 
The absorption maximum for Acyclovir in Distilled Water was found to be 252 
 
nm and it is shown in Figure 9.1. 
 
 
 
Fig. 9.1: λ max Observed for Acyclovir in Distilled Water 
 
9.1.4.2. Preparation of Standard Curve of Acyclovir by using Distilled Water: 
 
UV absorption spectrum of Acyclovir in Distilled Water showed λ max  at 252 
 
nm. Absorbance obtained for various concentrations  of Acyclovir in distilled water 
 
are given in Table 9.2. The graph of absorbance vs. concentration for Acyclovir was 
 
found  to  be linear  in  the  concentration  range of  4  -  20 μg/ml.  The  drug  obeys 
 
Beer - Lambert‘s law in the range of 4 - 20 μg/ml which is shown in Figure 9.2. The 
 
calibration parameters were shown in Table 9.3. 
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Table 9.2: Data of concentration and absorbance for Acyclovir for Distilled Water 
 
 
S. No. 
Concentration 
 
(µg/ml) 
 
Absorbance at 252nm 
1. 0 0 
2. 4 0.191 
3. 8 0.375 
4. 12 0.563 
5. 16 0.744 
6. 20 0.931 
 
 
Table 9.3: Data for calibration curve parameters in Distilled Water 
 
S. No. Parameters Values 
 
1. 
Correlation Coefficient 
 
(r) 
 
0.9999 
2. Slope (m) 0.04644 
3. Intercept (c) 0.00290 
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Fig. 9.2: Standard graph of Acyclovir in Distilled Water 
 
9.1.4.3. Determination of λ max of Acyclovir by using 0.1N HCl: 
The absorption maximum for Acyclovir in 0.1N HCl was found to be 255.5 nm 
and it is shown in Figure 9.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.3: λ max Observed for Acyclovir in 0.1N HCl 
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9.1.4.4. Preparation of Standard Curve of Acyclovir by using 0.1N HCl: 
 
The UV absorption spectrum of Acyclovir in 0.1N HCl shown λ max at 255.5nm. 
Absorbance obtained for various concentrations of Acyclovir in 0.1N HCl are given 
in Table 9.4. The graph of absorbance vs. concentration for Acyclovir was found to be 
linear in the concentration range of 4 - 20μg /ml. The drug obeys Beer - Lambert‘s 
law  in the  range  of 4 - 20μg  /ml  which  is shown  in Figure  9.4.  The  calibration 
parameters were shown in Table 9.5. 
Table 9.4: Data of concentration and absorbance for Acyclovir for 0.1N HCl 
 
 
S. No. 
Concentration 
 
(µg/ml) 
 
Absorbance at 255.5 nm 
1. 0 0.000 
2. 4 0.235 
3. 8 0.455 
4. 12 0.683 
5. 16 0.914 
6. 20 1.143 
 
Table 9.5: Data for calibration curve parameters in 0.1N HCl 
 
S. No. Parameters Values 
1. Correlation Coefficient (r) 0.9999 
2. Slope (m) 0.057 
3. Intercept (c) 0.0016 
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Fig. 9.4: Standard graph of Acyclovir in 0.1N HCl 
 
9.1.4.5. Determination of λ max of Acyclovir by using pH 7.4 Phosphate Buffer: 
 
The absorption maximum for Acyclovir in pH 7.4 Phosphate Buffer was found 
 
to be 253 nm and it is shown in Figure 9.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.5: λ max Observed for Acyclovir in pH 7.4 Phosphate Buffer 
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9.1.4.6. Preparation of Standard Curve of Acyclovir by using pH 7.4 Phosphate 
 
Buffer: 
 
UV absorption spectrum of Acyclovir in pH 7.4 Phosphate Buffer shown λ max at 
 
253  nm.  Absorbance  obtained  for  various  concentrations  of  Acyclovir  in  pH  7.4 
 
Phosphate Buffer are given in Table 9.6. The graph of absorbance vs. concentration 
for Acyclovir was found to be linear in the concentration range of 4 - 20μg/ml. The 
drug obeys Beer- Lambert‘s law in the range of 4 - 20μg/ml which is shown in Figure 
9.6. The calibration parameters were shown in Table 9.7. 
 
Table 9.6: Data of concentration and absorbance for Acyclovir in pH 7.4 Phosphate 
 
Buffer 
 
S.No. Concentration (µg/ml) Absorbance at 253 nm 
1. 0 0.000 
2. 4 0.247 
3. 8 0.494 
4. 12 0.736 
5. 16 0.982 
6. 20 1.227 
Acyclovir Loaded pH Sensitive Nanoparticle Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathure. Page 
1021021
02 
 
 
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
3
 n
m
 
 
Table 9.7: Data for calibration curve parameters in pH 7.4 Phosphate Buffer 
 
S. No. Parameters Values 
1. Correlation Coefficient (r) 0.9998 
2. Slope (m) 0.061331 
3. Intercept (c) 0.001333 
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Fig. 9.6: Standard graph of Acyclovir in pH 7.4 Phosphate Buffer 
 
9.1.5. Quantification of Drug: 
 
The percentage purity of drug was calculated by using calibration graph method 
 
(least square method) and the data has been shown in Table 9.8. 
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Table 9.8: Percentage purity of Acyclovir 
 
 
S. No. Percentage Purity (%) Average Percentage Purity* (%) 
1. 101.38  
 
 
101.03 ± 0.40 2. 100.57 
3. 101.06 
 
 
*All the values are expressed as mean ± SD, n = 3 
 
The percentage purity for Acyclovir in IP 2007 is not less than 98.0 % and not 
more than 102.0 % of the stated amount of Acyclovir. The percentage purity of 
Acyclovir was found to be 101.03 ± 0.40. So, it stands within the limits of IP 2007. 
9.1.6. FTIR Spectroscopy: 
 
 
 
 
 
Fig. 9.7: FTIR spectroscopy of pure drug Acyclovir 
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S. No Percentage  LOD *Avg. percentage LOD 
1 0.328  
 
0.407±0.070 2 0.431 
3 0.463 
 
 
Table 9.9: Characteristic frequencies in FTIR spectrum of Acyclovir 
 
S.No. Wave number (cm-1) Inference 
1 3441.02 N-H stretching 
2 3308.74 O-H stretching 
3 3099.14 C-H stretching 
4 1717.21 C=O stretching 
5 1541.50 C=C and C=N stretching 
6 1308.75 -CH2 Wagging and twisting 
7 1216.74 Aryl alkyl ether 
8 1105.79 C-O stretching 
9 1083.93 C-O-C stretching 
 
The  drug  was  confirmed  as  Acyclovir  with  results  obtained  from  FTIR 
 
spectrum analysis. 
 
9.1.7. Loss on Drying: 
 
The percentage loss on drying after 3 hours was found to be as follows 
 
Table 9.10: Percentage loss on drying for Acyclovir 
 
 
 
 
 
 
 
 
 
 
 
*All values are expressed as mean± S.D., n=3 
 
The  sample  passes  test  for  loss  on  drying  as  per  the  limit  specified  in  IP,  2007 
(N.M.T. 1%) 
Acyclovir Loaded pH Sensitive Nanoparticle Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathure. Page 
1051051
05 
 
 
 
 
 
9.2. Characterization of Nanoparticle: 
 
9.2.1. Particle Size Analysis: 
 
 
 
Fig. 9.8: Particle size graph of Acyclovir loaded pH sensitive nanoparticle 
 
formulation F6 
 
Particle size of the nanoparticle suspension was in the range from 273 to 365 nm. 
 
The mean particle size of the nanoparticle suspension 271 ±3.83 and poly dispersity 
 
index 0.734 ±0.36. Increase in particle size of nanoparticle suspension with decrease 
 
in the polydispersity index was observed with increase in the polymer content. The 
 
smaller particle size obtained at low polymer content may be due to high distribution 
 
efficiency of the internal polymer-solvent phase into the external phase. Increase in 
 
the  viscosity  of  internal  phase  with  increased  amount  of  polymer also  provides 
 
resistance  for  mass  transfer  in  turn  diffusion of  polymer-solvent  phase  into  the 
 
external phase leading to particle enlargement. The results are shown in Figure 9.8. 
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9.2.2. Estimation of Drug Content: 
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Fig. 9.9: Response surface plots showing effect of factorial variables on drug content 
 
The results of drug content are shown in the Table 9.11. The drug content of the 
 
nanoparticle  were in the range from 68.65 ±1.32 to 90.35 ±2.09% depends on the 
 
concentration of   polymer   added. The   maximum   drug content was   found   in 
 
formulation  F6 with 90.35 ±2.09%. Drug content was increases  with increasing  in 
 
concentration of polymer added to the formulation. 
 
9.2.3. Estimation of Drug Entrapment Efficiency: 
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Fig. 9.10: Response surface plots showing effect of factorial variables on drug 
 
entrapment efficiency 
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Table 9.11: Comparison of drug content with entrapment efficiency of formulation 
 
F1-F9 
 
S. No Batch code *Drug content (%) *Drug entrapment efficiency (%) 
1 F1 68.65±1.32 56.43±0.63 
2 F2 72.92±0.44 62.39±1.15 
3 F3 75.20±1.40 66.13±0.36 
4 F4 79.35±1.43 74.50±0.97 
5 F5 81.93±0.36 83.97±1.78 
6 F6 90.35±2.09 93.33±1.92 
7 F7 84.79±0.46 85.72±0.35 
8 F8 86.55±1.95 89.58±0.63 
9 F9 87.95±2.89 91.87±2.02 
* All the values expressed as mean ± mean S.D., n=3 
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Fig.   9.11: Comparative   graph   of drug   content   and   entrapment efficiency   of 
 
formulation F1-F9 
 
The entrapment efficiency of the acyclovir loaded pH sensitive nanoparticle was 
 
exhibit maximum in formulation F6 with 93.33±1.92%. Drug entrapment efficiency 
 
of the nanoparticle  was in the range from 56.43±0.63  to 93.33±1.92%.  The results 
 
were also in the Table 9.11. As the Eudragit
®
-EPO concentration increased from 100- 
 
200  mg  the encapsulation   efficiency  was  increased. When  the  Eudragit
®
-EPO 
 
concentration was maintained constant of 100 mg, the Pluronic
®  
F-68 concentration 
 
was varied as 25 mg, 50 mg, and 100 mg the encapsulation efficiency was slightly 
increased. The results indicate the Eudragit
®
-EPO concentration plays a major role in 
drug entrapment efficiency rather than the Pluronic
® 
F-68 concentration and shown in 
 
Figure 9.10. 
 
It can be explained on the basis  of lipophilic  - lipophilic  interaction  between 
 
acyclovir  and  Eudragit
®
-EPO.  Consequently with  increase  in  the  Eudragit
®
-EPO 
 
amount,   Acyclovir   gets preferentially   dispersed   in  the internal  organic  phase. 
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Pluronic
® 
F-68, also displayed similar trend and increase in encapsulation efficiency 
which can be due to the formulation  of interpenetrated  network chain between the 
hydrophobic portion of Pluronic
® 
F-68 with Eudragit
®
-EPO during precipitation. The 
comparative results of drug content and entrapment were shown in Figure 9.11. 
 
9.2.4 Development of Polynomial Equation: 
 
From the data of Experimental design and Parameters Table 9.11 for factorial 
formulations  F1  to  F9,  polynomial  equations  for  two  dependent  variables  (drug 
content  and  %  drug  entrapment  efficiency)  have  been  derived  using  PCP  Disso 
2000V3 software. The equation derived for drug content is: 
Y1= 80.8544 + 7.0867X1 + 3.4517 X2 …2 
The equation derived for % drug entrapment efficiency is: 
Y2=83.9333 + 13.7033 X1 + 5.7800X2 – 8.5800X1 2 …3 
In equation (2) positive sign for coefficient of X2 indicates when concentration 
of  stabilizer  (Pluronic  F-68)  is  increases  and  Positive  sign  for  coefficient  of  X1 
indicate positive effect of polymer concentration (Eugragit
®
-EPO) on drug content. 
In equation (3) positive sign for coefficient of X1  indicates that the % drug 
entrapment increases when concentration of polymer (Eugragit
®
-EPO) increases and 
positive sign for coefficient of X2  indicates that % drug entrapment of nanoparticles 
increases when concentration of stabilizer (Pluronic F-68) increases. 
9.2.4.1. Response Surface Plots: 
 
Graphical presentation of the data can help to show the relationship between 
response and independent variables. Graphs gave information similar to that of the 
mathematical  equations  obtained  from  statistical  analysis.  The  response  surface 
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graphs of drug content and % drug entrapment  are presented  in Fig.9.9,  and 9.10 
respectively. The response surface plots illustrated that as concentration of as polymer 
(Eugragit
®
-EPO) increases, the value of dependent variable i.e. drug content increases 
and as concentration  of stabilizer (Pluronic F-68) increases the value of dependent 
variable i.e. drug content decreases. Similarly the response surface plots for % drug 
entrapment shows positive effects of independent variable i.e. polymer concentration 
(Eugragit
®
-EPO) and negative effect of other independent variable i. e. concentration 
of stabilizer (Pluronic F-68). 
9.2.5 Fourier Transformer Infrared Spectroscopy (FTIR): 
 
 
 
Fig. 9.12: FTIR Spectrum of pure Acyclovir 
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Fig. 9.13: FTIR Spectrum of Acyclovir and Eudragit
®
-EPO 
 
 
 
Fig. 9.14: FTIR Spectrum of lyophilized nanoparticle formulation F6 
 
The   possible   drug   and   polymer   interaction   can be   studied   by   FTIR 
 
Spectroscopy.  According  to Table 9.12  and Figure  9.12 to Figure  9.14 the major 
 
peaks  observed  in  drug spectrum were  also observed  in spectrums of  drug  with 
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polymer, therefore it could indicate that there was no incompatibility  between drug 
and polymer. 
Table 9.12: Interpretation of FTIR spectrum 
 
 
 
 
 
S. No. 
 
Wave 
number 
(cm
-1
) 
 
 
 
Functional 
group 
Peak observed (Yes/No) 
 
Range 
 
(cm
-1
) 
 
 
 
Drug 
Drug + 
Eudragit
®
- 
EPO 
 
Formulation 
 
F6 
1 3441.02 N-H stretching 3500-3200 Yes Yes Yes 
2 3308.74 O-H stretching 3400-3200 Yes Yes Yes 
3 3099.14 C-H stretching 3100-3000 Yes Yes Yes 
 
4 
 
1717.21 
C=O 
 
stretching 
 
1740-1690 
 
Yes 
 
Yes 
 
Yes 
 
5 
 
1541.50 
C=C 
 
stretching 
 
1600-1430 
 
Yes 
 
Yes 
 
Yes 
 
6 
 
1308.75 
CH2-Wagging 
and  twisting 
 
1350-1150 
 
Yes 
 
Yes 
 
Yes 
 
7 
 
1216.74 
Aryl alkyl 
ether 
 
1275-1200 
 
Yes 
 
Yes 
 
Yes 
8 1105.79 C-O stretching 1200-1100 Yes Yes Yes 
 
9 
 
1083.93 
C-O-C 
 
stretching 
 
1150-1070 
 
Yes 
 
Yes 
 
Yes 
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9.2.6. Differential Scanning Calorimetory (DSC) Analysis: 
 
Table 9.13: Data for DSC thermogram parameters 
 
 
 
 
S.No. 
 
DSC thermogram 
sample 
Onset 
temperature 
(°C) 
Peak 
temperature 
(°C) 
Endset 
Temperature 
(°C) 
 
1 
 
Acyclovir 
 
251.13 
 
254.75 
 
257.83 
 
 
 
2 
 
Acyclovir + 
Eudragit
®
-EPO 
 
 
 
122.52 
 
 
 
124.89 
 
 
 
135.54 
3 Formuation F6 248.33 257.29 258.75 
 
 
 
 
 
 
 
Fig. 9.15: DSC Curve of pure Acyclovir 
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Fig. 9.16: DSC Curve of acyclovir and Eudragit
®
-EPO 
 
 
 
 
Fig. 9.17: DSC Curve of lyophilized nanoparticle formulation F6 
 
Figure  9.15,  9.16,  and  9.17  shows  the  DSC  thermograms  of  Acyclovir, 
Eudragit
®
-EPO   and  lyophilized   nanoparticle   suspension   respectively.   Acyclovir 
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exhibits a sharp melting endothermic  peak at 254.75ºC  (ΔH 321.29 J/g), where as 
 
Eudragit
®
-EPO showed a broad melting endrotherm peak at 124.89ºC (ΔH 8.66 J/g). 
 
The thermogram of lyophilized nanoparticle suspension displayed sharp endotherm at 
 
267.29
0
C  (ΔH  351.20 J/g),  corresponding  to Eudragit
®
-EPO  but  no drug  peak  it 
 
explains monotetic behavior of the system, where drug gets completely dissolve in 
 
below it temperature. It is evident that there was no chemical interaction between drug 
 
and polymer. The results are shown in table 9.13 and Figure 9.15, 9.16, and 9.17 
 
 
9.2.7. Scanning electron microscopy (SEM) analysis: 
 
 
 
 
Fig. 9.18: SEM Photograph of lyophilized nanoparticle formulation F6 
 
 
SEM  photograph  of  optimized  formulation  F6  were shown  in Figure  9.18. 
 
Acyclovir nanoparticle has shown smooth and spherical shape. The results is depends 
 
on the ratio of surfactant and polymer used in the optimized formulation F6. 
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9.2.8. Zeta Potential Measurement: 
 
 
 
Fig. 9.19: Plot of Zeta Potential distribution for the formulation F6 
 
The zeta potential values of the nanoparticle suspension had 30.7 ±2.4 mV. The 
 
formulation F6 exhibited strongly positive zeta potential values due to polycationic 
Eudragit
®    
EPO  comprising  of  various  ammonium  groups.  The  increasing  zeta 
potential values in initial batches may be attributed to Eudragit
®  
EPO available at the 
 
surface of the particles due to high viscosity of the external aqueous phase. 
 
9.3. In-Vitro Drug Release Study: 
 
The release rate of nanoparticle depend upon 
 
i)  desorption of   the surface-bound/adsorbed drug;   ii) diffusion through   the 
 
nanopaticle matrix; iii) diffusion (in case of nanocapsule) through the polymer wall; 
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iv) nanoparticle matrix erosion: and v) a combined erosion/diffusion  process. Thus, 
diffusion and biodegradation govern the process of drug release. 
The mechanism of drug release from nanoparticle is determined by different 
physical–chemical phenomena. The exponent n has been proposed as indicative of the 
release  mechanism.  In this  context,  n ≤ 0.43  indicates  Fickian  release  and n = 1 
indicates  a purely relaxation  controlled  delivery. Intermediate  values 0.43 < n < 1 
indicate an anomalous behavior (non-Fickian kinetics corresponding to coupled 
diffusion/polymer relaxation. 
The  average  percentage  release  was  fitted  into  different  release  models:  zero 
order,  first  order,  Higuchi‘s  square  root  plot  and  Korsmeyer-Peppas  models.  The 
models  giving  a correlation  coefficient  close  to  unity  were  taken  as  the  order  of 
release In vitro drug release data of all selected factorial formulations was subjected 
to goodness of fit test by linear regression analysis according to zero order and first 
order kinetic  equations,  Higuchi‘s,  and Korsmeyer-Peppas  models  to ascertain  the 
mechanism of drug release. It is evident that values of ‗r‘ of factorial formulation F6 
was found to be 0.997. This data reveals that drug release follows zero order release 
kinetics with non-fickian diffusion mechanism Drug release for selected factorial 
formulation F6 are 94.46±0.57% at the end of 13 hours. Kinetic exponent ‗n‘ for these 
formulations   indicate  diffusion  through  the  nanoparticle  matrix  as  well  matrix 
erosion.  Finally,  it can  be  concluded  that the  different  drug  release  rates  may  be 
attributed to different sizes of the nanoparticle. It is expected as the particle size of 
Eudragit
®
-EPO nanoparticle is smaller, their surface areas will be more and the drug 
 
release is faster 
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Table 9.14: In-vitro drug release data of formulation F1 
 
Time 
 
(hours) 
 
DR* 
(%) 
 
Amount (mg) 
 
% DE 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 13.37±1.06 1.34 6.00 0.50 
2 18.42±1.73 1.84 11.20 0.92 
3 23.80±1.64 2.38 15.21 1.22 
4 31.52±1.22 3.15 18.43 1.58 
5 36.95±1.79 3.70 21.37 2.02 
6 41.41±1.51 4.14 24.20 2.44 
7 50.05±1.06 5.01 27.21 3.17 
8 57.50±2.24 5.75 30.39 3.62 
9 65.87±1.20 6.59 33.79 4.43 
10 70.81±1.48 7.08 37.27 4.73 
11 77.39±0.81 7.74 40.59 5.18 
12 81.47±2.67 8.15 43.66 5.30 
* All the values expressed as mean ± mean S.D., n=3 
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Fig. 9.20: In vitro drug release profile of formulation F1 
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Table 9.15: In-vitro drug release data of formulation F2 
 
Time 
 
(hours) 
 
DR* 
(%) 
 
Amount (mg) 
 
% DE 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 10.32±1.31 1.03 5.54 0.50 
2 18.85±0.86 1.89 9.91 0.87 
3 25.49±1.33 2.55 13.61 1.34 
4 29.67±0.52 2.97 16.96 1.70 
5 37.66±0.68 3.77 20.22 2.28 
6 42.77±1.39 4.28 23.68 2.83 
7 51.25±1.85 5.13 27.24 3.35 
8 55.16±2.17 5.52 30.71 3.75 
9 66.57±0.68 6.66 34.21 4.37 
10 69.40±0.65 6.94 37.53 4.51 
11 79.07±1.80 7.91 40.87 5.40 
12 84.07±1.30 8.41 44.32 5.68 
* All the values expressed as mean ± mean S.D., n=3 
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Table 9.16: In-vitro drug release data of formulation F3 
 
 
Time 
 
(hours) 
 
 
DR* 
(%) 
 
 
Amount (mg) 
 
 
% DE 
 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 13.64±0.98 1.36 5.60 0.50 
2 19.56±1.06 1.96 10.38 0.91 
3 23.42±2.20 2.34 14.42 1.33 
4 30.70±2.81 3.07 18.24 1.82 
5 37.77±1.39 3.78 21.62 2.06 
6 42.17±2.78 4.22 24.37 2.30 
7 49.45±1.99 4.95 27.10 3.00 
8 55.81±1.05 5.58 30.17 3.68 
9 64.29±2.13 6.43 33.59 4.43 
10 70.54±2.62 7.05 37.09 4.77 
11 72.82±2.62 7.28 40.22 4.86 
12 84.62±1.47 8.46 43.34 5.76 
13 87.28±0.98 8.73 46.56 6.03 
* All the values expressed as mean ± mean S.D., n=3 
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Table 9.17: In-vitro drug release data of formulation F4 
 
Time 
 
(hours) 
 
 
DR* 
(%) 
 
 
Amount (mg) 
 
 
% DE 
 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 12.28±0.41 1.23 5.63 0.50 
2 17.60±1.24 1.76 10.33 0.90 
3 25.70±1.07 2.57 14.32 1.33 
4 31.84±1.22 3.18 17.79 1.68 
5 40.32±1.31 4.03 21.20 2.29 
6 44.24±0.20 4.42 24.48 2.56 
7 53.15±1.06 5.32 27.81 3.32 
8 57.28±1.24 5.73 31.19 3.61 
9 65.60±1.83 6.56 34.61 4.35 
10 68.69±1.40 6.87 38.04 4.64 
11 76.41±1.72 7.64 41.39 5.23 
* All the values expressed as mean ± mean S.D., n=3 
 
 
 
90 
80 
70 
60 
50 
40                                                                                                                                 F4 
30 
20 
10 
0 
0        1        2        3        4        5        6        7        8        9       10     11 
Time in hours 
 
 
Fig. 9.23: In vitro drug release profile of formulation F4 
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Table 9.18: In-vitro drug release data of formulation F5 
 
Time 
 
(hours) 
 
 
DR* 
(%) 
 
 
Amount (mg) 
 
 
% DE 
 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 14.23±1.08 1.42 6.86 0.50 
2 21.52±0.93 2.15 12.26 0.86 
3 27.88±1.73 2.79 16.18 1.16 
4 33.53±1.40 3.35 19.76 1.72 
5 38.80±1.42 3.88 23.09 1.98 
6 47.93±1.96 4.79 26.67 2.86 
7 53.09±0.49 5.31 30.32 3.04 
8 60.49±1.74 6.05 33.54 3.42 
9 66.63±0.71 6.66 36.80 4.07 
10 73.75±0.73 7.38 40.12 4.49 
11 79.13±1.66 7.91 43.39 4.99 
12 85.54±1.14 8.55 46.59 5.36 
* All the values expressed as mean ± mean S.D., n=3 
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Fig. 9.24: In vitro drug release profile of formulation F5 
Acyclovir Loaded pH Sensitive Nanoparticle Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathure. Page 123 
 
 
P
er
ce
n
ta
g
e 
d
ru
g
 r
e
le
a
se
 
 
Table 9.19: In-vitro drug release data of formulation F6 
 
Time 
 
(hours) 
 
 
DR* 
(%) 
 
 
Amount (mg) 
 
 
% DE 
 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 9.40±0.65 0.94 4.80 0.50 
2 15.87±1.06 1.59 8.38 0.83 
3 22.82±0.73 2.28 11.72 1.44 
4 31.63±0.57 3.16 15.70 2.09 
5 38.86±0.52 3.89 19.76 2.47 
6 44.45±1.14 4.45 23.36 2.79 
7 51.30±1.55 5.13 26.80 3.34 
8 59.56±0.93 5.96 30.35 3.89 
9 66.79±1.42 6.68 33.99 4.44 
10 74.13±0.81 7.41 37.69 4.97 
11 81.52±2.17 8.15 41.45 5.51 
12 87.82±1.14 8.78 45.11 5.82 
13 94.46±0.57 9.45 48.68 6.36 
* All the values expressed as mean ± mean S.D., n=3 
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Fig. 9.25: In vitro drug release profile of formulation F6 
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Table 9.20: In-vitro drug release data of formulation F7 
 
Time 
 
(hours) 
 
 
DR* 
(%) 
 
 
Amount (mg) 
 
 
% DE 
 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 12.77±0.98 1.28 6.12 0.50 
2 19.67±0.65 1.97 11.36 0.91 
3 25.65±0.65 2.57 15.29 1.19 
4 33.69±0.98 3.37 18.76 1.72 
5 37.06±1.94 3.71 21.89 1.95 
6 44.72±1.14 4.47 25.04 2.72 
7 53.64±1.47 5.36 28.73 3.41 
8 57.61±1.27 5.76 32.16 3.44 
9 64.51±0.98 6.45 35.36 4.14 
10 72.50±1.47 7.25 38.76 4.72 
* All the values expressed as mean ± mean S.D., n=3 
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Fig. 9.26: In vitro drug release profile of formulation F7 
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Table 9.21: In-vitro drug release data of formulation F8 
 
Time 
 
(hours) 
 
 
DR* 
(%) 
 
 
Amount (mg) 
 
 
% DE 
 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 15.38±1.39 1.54 8.21 0.50 
2 20.59±1.00 2.06 13.44 0.72 
3 28.42±1.22 2.84 17.38 1.24 
4 32.22±1.14 3.22 20.68 1.38 
5 40.38±1.07 4.04 23.68 2.03 
6 49.83±1.55 4.98 27.31 2.80 
7 57.88±0.73 5.79 31.20 3.23 
8 62.71±1.08 6.27 34.85 3.57 
9 71.25±1.14 7.13 38.51 4.22 
10 78.04±0.59 7.80 42.17 4.57 
* All the values expressed as mean ± mean S.D., n=3 
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Fig. 9.27: In vitro drug release profile of formulation F8 
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Table 9.22: In-vitro drug release data of formulation F9 
 
Time 
 
(hours) 
 
 
DR* 
(%) 
 
 
Amount (mg) 
 
 
% DE 
 
 
MDT 
0 0.00 0.00 0.00 0.00 
1 12.66±0.98 1.27 6.03 0.50 
2 21.73±2.04 2.17 11.42 0.94 
3 27.06±0.90 2.71 15.60 1.23 
4 31.46±1.14 3.15 19.11 1.67 
5 37.82±1.73 3.78 22.14 1.90 
6 45.70±0.50 4.57 25.31 2.75 
7 51.63±0.50 5.16 28.74 3.11 
8 58.86±0.57 5.89 32.03 3.61 
9 64.29±2.13 6.43 35.19 3.94 
10 67.39±1.51 6.74 38.06 4.15 
11 74.83±1.14 7.48 40.94 4.95 
12 82.34±1.42 8.23 44.09 5.63 
* All the values expressed as mean ± mean S.D., n=3 
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Fig. 9.28: In vitro drug release profile of formulation F9 
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Table 9.23: Comparative drug release data for all formulations 
 
Time in 
hours 
Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 13.37±1.06 10.32±1.39 13.64±0.98 12.28±0.41 14.23±1.08 9.40±0.65 12.77±0.98 15.38±1.39 12.66±0.98 
2 18.42±1.73 18.85±0.86 19.56±1.06 17.60±1.24 21.52±0.93 15.87±1.06 19.67±0.65 20.59±1.00 21.73±2.04 
3 23.80±1.64 25.49±1.33 23.42±2.20 25.70±1.07 27.88±1.73 22.82±0.73 25.65±0.65 28.42±1.22 27.06±0.90 
4 31.52±1.22 29.67±0.52 30.70±2.81 31.84±1.22 33.53±1.40 31.63±0.57 33.69±0.98 32.22±1.14 31.46±1.14 
5 36.95±1.79 37.66±0.68 37.77±1.39 40.32±1.31 38.80±1.42 38.86±0.52 37.06±1.94 40.38±1.07 37.82±1.73 
6 41.41±1.51 42.77±1.39 42.17±2.78 44.24±2.20 47.93±1.96 44.45±1.14 44.72±1.14 49.83±`1.55 45.70±0.50 
7 50.05±1.06 51.25±1.85 49.45±1.99 53.15±1.06 53.09±0.49 51.30±1.55 53.64±1.47 57.88±0.73 51.63±0.50 
8 57.50±2.24 55.16±2.17 55.81±1.05 57.28±1.24 60.49±1.74 59.56±0.93 57.61±1.27 62.71±1.08 58.86±0.57 
9 65.87±1.20 66.57±0.68 64.29±2.13 65.60±1.83 66.63±1.71 66.79±1.42 64.51±0.98 71.25±1.14 64.29±2.13 
10 70.81±1.48 69.40±0.65 70.54±2.62 68.69±1.40 73.75±0.73 74.13±0.81 72.50±1.47 78.04±0.59 67.39±1.51 
11 77.39±0.81 79.07±1.80 72.82±2.62 76.41±1.72 79.13±0.66 81.52±2.17 - - 74.83±1.14 
12 81.47±2.67 84.07±1.30 84.62±1.47 - 85.54±1.14 87.82±1.14 - - 82.34±1.42 
13 - - 87.28±0.98 - - 94.46±0.57 - - - 
 
 
 
All the values expressed as mean ± mean S.D., n=3 
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Fig. 9.29: Comparative drug release profile between formulations F1 to F3 
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Fig. 9.30: Comparative drug release profile between formulations F4 to F6 
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Fig. 9.31: Comparative drug release profile between formulations F7 to F9 
 
9.3.1 Kinetics of in-vitro drug release: 
 
Table 9.24: Kinetics of in-vitro drug release profile for all Formulation 
 
 
 
 
Formulatio 
n code 
Zero 
order 
R
2 
value 
First 
order 
R
2 
value 
 
 
Higuchi’s 
 
R
2 
value 
Peppas  
 
 
 
Best fit 
 
 
R
2 
value 
 
 
n value 
F1 0.994 0.943 0.937 0.981 0.952 Zero order 
F2 0.995 0.920 0.935 0.995 0.929 Zero order 
F3 0.994 0.905 0.938 0.980 0.884 Zero order 
F4 0.993 0.970 0.981 0.992 0.960 Zero order 
F5 0.989 0.937 0.952 0.990 0.937 Peppas 
F6 0.997 0.835 0.931 0.995 0.963 Zero order 
F7 0.992 0.968 0.947 0.991 0.918 Zero order 
F8 0.992 0.953 0.940 0.976 0.856 Zero order 
F9 0.991 0.950 0.955 0.993 0.907 Peppas 
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Fig. 9.32: Best fit model for formulation F1 (Zero order) 
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Fig. 9.33: Best fit model for formulation F2 (Zero order) 
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Fig. 9.34: Best fit model for formulation F3 (Zero order) 
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Fig. 9.35: Best fit model for formulation F4 (Zero order) 
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Fig. 9.36: Best fit model for formulation F5 (Peppas) 
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Fig. 9.37: Best fit model for formulation F6 (Zero order) 
Acyclovir Loaded pH Sensitive Nanoparticle Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathure. Page 
1321321
32 
 
 
lo
g
 %
 d
ru
g
 r
e
le
a
se
 
P
er
c
en
ta
g
e 
d
ru
g
 r
e
le
a
se
 
P
er
c
en
ta
g
e 
d
ru
g
 r
e
le
a
se
 
 
 
80                                           R² = 0.992 
 
60 
 
40 
 
20 
 
0 
0                2                4                6                8               10              12 
Time in hours 
 
Fig. 9.38: Best fit model for formulation F7 (Zero order) 
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Fig. 9.39: Best fit model for formulation F8 (Zero order) 
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Fig. 9.40: Best fit model for formulation F9 (Peppas) 
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9.4. Stability study: 
 
Table 9.25: Drug content and entrapment efficiency after 90 days storage of formulation F6 
 
 
 
 
S.No. 
 
 
 
Time 
 
*Drug content 
 
*Entrapment efficiency 
 
4 ± 1
0
C 
25
0 
± 2
0
C / 60 
 
± 5 % RH 
 
4 ± 1
0
C 
25
0 
± 2
0
C / 60 
 
± 5 % RH 
1 0 Days 90.35±2.09 90.35±2.09 93.33±1.92 93.33±1.92 
2 30 Days 90.23±0.70 90.00±1.47 93.03±0.49 92.86±0.26 
3 60 Days 90.05±0.35 89.59±0.53 92.63±0.20 91.69±0.35 
4 90 Days 89.65±0.70 88.24±0.66 92.16±0.10 90.70±0.44 
* All the values expressed as mean ± mean S.D., n=3 
 
 
 
 
 
 
 
C ± 1°C 
 
 
 
± 2°C 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.41: Stability study (drug content) of lyophilized Nanoparticle formulation F6 
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Fig. 9.42: Stability study (drug entrapment efficiency) of lyophilized nanoparticle 
 
formulation F6 
 
The results is indicates that there was no change in appearance and settling 
 
behavior when observed visually. The drug content and entrapment efficiency after 90 
 
days of the stability testing at different storage condition are shown in Table 9.25 and 
 
Figure 9.41 and 9.42. By comparing this data with initial data it was observed that 
 
there is overall decrease in % entrapment efficiency. 
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Fig. 9.43: Stability study (In-vitro drug release) of lyophilized nanoparticle 
 
formulation F6 
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Table 9.26: In-vitro drug release after 90days stability study of formulation F6 
 
 
 
 
 
 
S.No. 
 
 
 
Time / 
Temperature 
 
*Percentage of in-vitro drug release 
 
 
4 ± 1
0
C 
25
0 
± 2
0
C / 60 
 
± 5 % RH 
 
1 
 
0 Days 
 
94.46±0.57 
 
94.46±0.57 
 
2 
 
30 Days 
 
94.35±0.28 
 
94.29±0.24 
 
3 
 
60 Days 
 
94.02±0.16 
 
93.91±0.18 
 
4 
 
90 Days 
 
93.86±0.16 
 
93.48±0.24 
* All the values expressed as mean ± mean S.D., n=3 
 
The  percentage  in-vitro  drug  release  studies  after  90  days  of the  stability 
testing at different storage conditions are shown in Table 9.26 and Figure 9.43. By 
comparing  this data with initial data it was observed that there is no change in % 
percentage drug release. 
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10.SUMMARY AND CONCLUSION 
 
 
 
 
 
The present study was aimed to formulate pH sensitive nanoparticle by using 
polymers  Eudragit
®
-EPO  and surfactant  Pluronic
®
-F  68 in order  to treat  the viral 
infections   an   attempt   was   made   to   study   the   effect   of   Eudragit
®
-EPO   and 
Pluronic
®
-F 68 on characterization of nanoparticle. 
Literature survey on nanotechnology  proved that the polymer and surfactant 
selected for the present study have good nanoparticle forming property there are some 
reports with this new combination of polymer and surfactant used for research work. 
Preformulation study was carried out for the drug identification. The 
identification of drug was determined by melting point, solubility, λ max, FTIR and 
loss on drying. The values of the study obeys that procured drug was confirmed as 
acyclovir. 
The present studies are focused on application of 3
2  
factorial design for the 
 
formation of nanoparticle with desired particle size. The effect ratio of polymer and 
stabilizer were found to influence the particle size, drug content and entrapment 
efficiency. 
pH sensitive nanoparticle of acyclovir were prepared by nanoprecipitation 
technique.  The  prepared  nanoparticles  were  characterized  for  particle  size,  drug 
content and entrapment efficiency. All the characterized parameters shows that 
formulation F6 nanoparticle with desired size, high drug content and high entrapment 
efficiency. 
Acyclovir Loaded pH Sensitive Nanoparticle Summary and Conclution 
Adhiparasakthi College Of Pharmacy, Melmaruvathur Page 138 
 
 
 
The drug and polymer compatibility study was carried out by FTIR and DSC 
analysis. The data‘s showed that there was no interaction between drug and polymer 
used in formulation F6. 
From the SEM analysis study the formulation F6 shows that the particles are 
smooth and spherical in shape. 
Formulation  F6  shows  the  zeta  potential  value  about  30  mV.  It  can  be 
concluded that formulation F6 shown to be stable in suspension as the surface charge 
prevents aggregation of particle. 
In-vitro drug release studies closely indicate that formulation  F6 was found 
maximum amount of drug released among nine formulations at the end of 13 hours. 
The value of the in-vitro drug release was fitted with the kinetic modeling for 
all formulation using PCP disso software. As per the kinetic drug release modify the 
formulation F6 are released the drug by following zero order drug release. 
Form the stability data it can be concluded there was no significant change in 
drug  content,  drug  entrapment  efficiency  and  in-vitro  drug  release.  Hence  the 
formulation F6 is stable formulation. 
The  overall  studies   concluded   that  formulation   F6  composed   of  drug, 
Eudragit
®
-EPO  and pluronic
®
-F  68 in the ratio of 1:1.5:1 showed satisfactory  and 
better release profile. Hence the formulation F6 considered as best formulation. 
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11. FUTURE PROSPECTS 
 
 
 
 
The present study focused on acyclovir loaded self assembled pH sensitive 
nanoparticle preparation using Eudragit
®
-EPO and surfactant Pluronic
®
-F 68 the 
nanoparticle  prepared  by  nanoprecipitation method.  The  prepared  nanoparticles  were 
evaluated by in-vitro parameters. Along with in-vitro studies there is a need to perform 
in-vivo studies using animal model. 
In future in-vivo studies will be conducted to set in-vitro in-vivo correlation which 
is necessary for the successful formulation development. 
In future the long term stability studies are required to know the shelf life of the 
prepared nanoparticle. 
The various formulations will be developed with acyclovir using other polymer 
and stabilizer in future. 
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